

MIT Open Access Articles

TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

Citation: Fraenkel, Ernest. 2022. "TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A." *Nature*, 603 (7899).

As Published: 10.1038/S41586-022-04436-3

Publisher: Springer Science and Business Media LLC

Persistent URL: <https://hdl.handle.net/1721.1/147818>

Version: Final published version: final published article, as it appeared in a journal, conference proceedings, or other formally published context

Terms of use: Creative Commons Attribution 4.0 International license



TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A

<https://doi.org/10.1038/s41586-022-04436-3>

Received: 2 April 2021

Accepted: 18 January 2022

Published online: 23 February 2022

Open access

 Check for updates

Anna-Leigh Brown^{1,9†}, Oscar G. Wilkins^{1,2,9†}, Matthew J. Keuss^{1,9†}, Sarah E. Hill^{3,9†}, Matteo Zanovello¹, Weaverly Colleen Lee¹, Alexander Bampton^{4,5}, Flora C. Y. Lee^{1,2}, Laura Masino², Yue A. Qi⁶, Sam Bryce-Smith¹, Ariana Gatt^{4,5}, Martina Hallegger^{1,2}, Delphine Fagegaltier⁷, Hemali Phatnani⁷, NYGC ALS Consortium^{*}, Jia Newcombe⁸, Emil K. Gustavsson^{4,9}, Sahba Seddighi^{3,10}, Joel F. Reyes³, Steven L. Coon¹¹, Daniel Ramos^{3,6}, Giampietro Schiavo^{1,12}, Elizabeth M. C. Fisher¹, Towfique Raj^{13,14,15,16}, Maria Secier¹⁷, Tammaryn Lashley^{4,5}, Jernej Ule^{1,2,18}, Emanuele Buratti¹⁹, Jack Humphrey^{13,14,15,16}, Michael E. Ward^{9,20} & Pietro Fratta^{1,20}

Variants of *UNC13A*, a critical gene for synapse function, increase the risk of amyotrophic lateral sclerosis and frontotemporal dementia^{1–3}, two related neurodegenerative diseases defined by mislocalization of the RNA-binding protein TDP-43^{4,5}. Here we show that TDP-43 depletion induces robust inclusion of a cryptic exon in *UNC13A*, resulting in nonsense-mediated decay and loss of UNC13A protein. Two common intronic *UNC13A* polymorphisms strongly associated with amyotrophic lateral sclerosis and frontotemporal dementia risk overlap with TDP-43 binding sites. These polymorphisms potentiate cryptic exon inclusion, both in cultured cells and in brains and spinal cords from patients with these conditions. Our findings, which demonstrate a genetic link between loss of nuclear TDP-43 function and disease, reveal the mechanism by which *UNC13A* variants exacerbate the effects of decreased TDP-43 function. They further provide a promising therapeutic target for TDP-43 proteinopathies.

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating adult-onset neurodegenerative disorders with shared genetic causes and common pathological aggregates⁶. Genome-wide association studies (GWAS) have repeatedly demonstrated a shared risk locus for ALS and FTD in the crucial synaptic gene *UNC13A*, although the mechanism underlying this association has remained unknown^{1–3}.

ALS and FTD are pathologically defined by cytoplasmic aggregation and nuclear depletion of TAR DNA-binding protein 43 (TDP-43) in more than 97% of ALS cases and 45% of FTD cases^{4,5} (frontotemporal lobar degeneration (FTLD) due to TDP-43 proteinopathy (FTLD-TDP)). TDP-43 is an RNA-binding protein (RBP) that resides primarily in the nucleus and has key regulatory roles in RNA metabolism, including as a splicing repressor. Upon loss of nuclear TDP-43—an early pathological feature in TDP-43-associated ALS (ALS-TDP) and FTLD-TDP—non-conserved intronic sequences are de-repressed and erroneously included in

mature RNAs. These events are referred to as cryptic exons (CEs) and often lead to premature stop codons and transcript degradation, or premature polyadenylation⁷. One such CE occurs in the stathmin 2 (*STMN2*) transcript^{8,9}. This *STMN2* CE is selectively expressed in affected tissue, and its level correlates with TDP-43 phosphorylation, enabling it to serve as a functional readout for TDP-43 proteinopathy^{8–10}. However, a link between CEs and disease risk has not yet been established.

Here we report the presence of a CE in *UNC13A*, which is present at high levels in neurons from patients with ALS and FTLD-TDP. This CE promotes nonsense-mediated decay (NMD) and *UNC13A* transcript and protein loss. Notably, intronic risk-associated single nucleotide polymorphisms (SNPs) for ALS and FTD in *UNC13A* promote increased inclusion of this CE. Collectively, our findings reveal the molecular mechanism behind one of the top GWAS hits for ALS and FTD and provide a promising new therapeutic target for TDP-43 proteinopathies.

¹UCL Queen Square Motor Neuron Disease Centre, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK. ²The Francis Crick Institute, London, UK. ³National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA. ⁴Queen Square Brain Bank, UCL Queen Square Institute of Neurology, University College London, London, UK. ⁵Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK. ⁶Center for Alzheimer's and Related Dementias, National Institutes of Health, Bethesda, MD, USA. ⁷Center for Genomics of Neurodegenerative Disease, New York Genome Center (NYGC), New York, NY, USA. ⁸NeuroResource, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, UK. ⁹Great Ormond Street Institute of Child Health, Genetics and Genomic Medicine, University College London, London, UK. ¹⁰Medical Scientist Training Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ¹¹Molecular Genomics Core, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, USA. ¹²UK Dementia Research Institute, University College London, London, UK. ¹³Nash Family Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁴Ronald M. Loeb Center for Alzheimer's Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁵Department of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁶Estelle and Daniel Maggini Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁷Department of Genetics, Evolution and Environment, UCL Genetics Institute, University College London, London, UK. ¹⁸Department of Molecular Biology and Nanobiotechnology, National Institute of Chemistry, Ljubljana, Slovenia. ¹⁹Molecular Pathology Lab, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy. ²⁰These authors contributed equally: Anna-Leigh Brown, Oscar G. Wilkins, Matthew J. Keuss, Sarah E. Hill. *A list of authors and their affiliations appears online. ✉e-mail: wardme@nih.gov; p.fratta@ucl.ac.uk




Fig. 1 | TDP-43 depletion in neurons leads to altered splicing in synaptic genes *UNC13A* and *UNC13B*. **a**, Differential splicing analysis by MAJIQ³³ in control ($n = 4$) and CRISPRi TDP-43 depleted (KD) ($n = 3$) iPSC cell-derived cortical-like i³Neurons. Each point denotes a splice junction. **b**, Representative sashimi plots showing cryptic exon (CE) inclusion between exons 20 and 21 of *UNC13A* upon TDP-43 knockdown. **c**, **f**, Schematics showing intron retention (IR) (orange; bottom), TDP-43 binding region²² (green), and two ALS- and FTLN-associated SNPs (red) in *UNC13A* (**c**) and *UNC13B* (**f**). **d**, LocusZoom plot of the *UNC13A* locus in the most recent ALS GWAS¹⁵; the dashed line indicates the risk threshold used in that study. Lead SNP *rs12973192* is plotted as a purple diamond, other SNPs are coloured by linkage disequilibrium (LD) with *rs12973192* in European individuals from 1000 Genomes. Ref. var., reference variant. **e**, Representative sashimi plot of *UNC13B* showing inclusion of the FSE

upon TDP-43 knockdown. **g**, BaseScope detection of *UNC13A* CE (white puncta) in control (top) and TDP-43-knockdown (bottom) i³Neurons co-stained for TDP-43 (green), neuronal processes (stained for TUBB3, pink) and nuclei (blue). Scale bar, 5 μ m. **h**, Quantification of RT-PCR products using iPSC cell-derived neurons made from an independent iPSC cell line, NCRM5, with a non-targeting control short guide RNA (sgRNA) (sgTARDBP-), an intermediate TDP-43 knockdown (sgTARDBP+) or stronger TDP-43 knockdown (sgTARDBP++). Data are mean \pm s.e.m. sgControl, $n = 6$; sgTARDBP+, $n = 5$; sgTARDBP++, $n = 6$; one-way ANOVA with multiple comparisons. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$. **i**, Schematic of nanopore long reads quantified in **j**, Extended Data Figs. 2d, e, 5e, f, **j**, Percentage of targeted *UNC13A* long reads with TDP-43-regulated splice events that contain CE, intron retention or both in TDP-43-knockdown SH-SY5Y cells.

UNC13A cryptic exon production on TDP-43 knockdown

To identify novel CEs promoted by TDP-43 depletion, we performed RNA sequencing (RNA-seq) on human induced pluripotent stem (iPS) cell-derived cortical-like i³Neurons, in which we reduced TDP-43 expression using CRISPR inhibition^{11–13} (CRISPRi). Differential splicing and expression analyses identified 179 CEs, including several that have been reported previously, in genes including *AGRN*, *RAP1GAP*, *PFKP* and *STMN2*^{7,8,14} (Fig. 1a, Supplementary Data 1, 2). We examined splicing, expression, ALS GWAS¹⁵ risk genes and diagnostic panel genes for ALS and FTD¹⁶. Of the 179 CE-harboring genes, only the synaptic gene *UNC13A* was also an ALS–FTD risk gene (Fig. 1b, c, Supplementary Table 1). *UNC13A* polymorphisms modify both disease risk and progression in ALS and FTLN–TDP^{1–3,15,17–19}, suggesting a potential functional relationship between TDP-43, *UNC13A* and disease risk. Inspection of *UNC13A* splicing revealed the presence of a CE, occurring in two forms distinguishable by their size, between exons 20 and 21 after TDP-43 knockdown (Fig. 1b), and increased intron retention between exons 31 and 32 (Extended Data Fig. 1a). One ALS–TDP and FTLN–TDP risk SNP—*rs12973192*—lies 16 bp inside the CE (hereafter referred to as the CE SNP). Another SNP—*rs12608932*—is located 534 bp downstream of the donor splice site of the CE within the same intron (hereafter referred to as the intronic SNP) (Fig. 1c). There are five polymorphisms associated

with ALS risk in *UNC13A*¹⁵. All are in high linkage disequilibrium with both the CE and intronic SNPs in European populations, with an allele frequency of 0.3423 and 0.3651, respectively²⁰ (Fig. 1d). The proximity of the disease-associated SNPs to the *UNC13A* CE suggests that the SNPs may influence *UNC13A* splicing. Of note, we also observed robust mis-splicing in *UNC13B*, which encodes another member of the UNC13 synaptic protein family (Fig. 1e, f). TDP-43 knockdown led to the inclusion of an annotated frame-shift-inducing exon between exons 10 and 11 in *UNC13B*, hereafter referred to as the *UNC13B* frameshift exon (FSE), and increased intron retention between exon 21 and 22 (Fig. 1e, f, Extended Data Fig. 1b).

We validated the *UNC13A* CE in i³Neurons by in situ hybridization, which showed a primarily nuclear localization and occurred predominantly in TDP-43-knockdown neurons (Fig. 1g, Extended Data Fig. 1c). To confirm the CE was not restricted to neurons derived from a single iPSC cell line, we performed TDP-43 knockdown in independent i³Neurons using two different guides leading to different levels of TDP-43 knockdown (Extended Data Fig. 1d, e). CE expression was restricted to cells with TDP-43 knockdown in both lines, and correlated with the level of TDP-43 knockdown (Fig. 1h, Extended Data Fig. 1f, g). We also detected these splicing changes in RNA-seq data we generated from TDP-43 depleted SH-SY5Y and SK-N-DZ neuronal lines, and publicly available RNA-seq from iPSC cell-derived motor neurons⁹ and SK-N-DZ datasets²¹ (Extended Data Fig. 1h–k, Supplementary Table 2). We note




Fig. 2 | *UNC13A* and *UNC13B* are downregulated after TDP-43 knockdown owing to the production of NMD-sensitive transcripts. **a**, Ribosome profiling of TDP-43-knockdown *i*³Neurons shows a reduction in ribosome occupancy of *STMN2*, *UNC13A* and *UNC13B* transcripts. **b**, Mass spectrometry-based proteomic analysis shows dose-dependent reduction in protein abundance of *UNC13A* and TDP-43 upon TDP-43 knockdown in *i*³Neurons. *n* = 6 biological replicates. Two-sample *t*-test. **c**, Protein and RNA quantification of TDP-43, *UNC13A* and *UNC13B* in SH-SY5Y with varying levels of doxycycline-inducible TDP-43 knockdown. *n* = 3 biological replicates. **d**, Transcript expression upon treatment with CHX suggests that *UNC13A* and *UNC13B*, but not *STMN2*, are sensitive to NMD. *HNRNPL* is used as a positive control. *n* = 7 biological replicates (*UNC13A*, *HNRNPL* and *STMN2*) and 8 biological replicates (*UNC13B*). One-sample *t*-test. Data are mean ± s.e.m. (**b–d**).

that the expression of these events was lowest in the SH-SY5Y experiment, which also showed the weakest TDP-43 knockdown (Extended Data Fig. 1l). Using stronger TDP-43 knockdown, we validated the *UNC13A* CE by PCR with reverse transcription (RT-PCR) and Sanger sequencing in SH-SY5Y and SK-N-DZ cell lines (Extended Data Fig. 2a).

In support of a direct role for TDP-43 regulation of *UNC13A* and *UNC13B*, we found multiple TDP-43-binding peaks²² both downstream and within the body of the *UNC13A* CE (Fig. 1c) and intron retention (Extended Data Fig. 1a). Additionally, TDP-43-binding peaks²² were present near both splice events in *UNC13B* (Fig. 1f, Extended Data Fig. 1b). Additional iCLIP of endogenous TDP-43 in SH-SY5Y cells confirmed enhanced binding near the *UNC13A* CE and intron retention and *UNC13B* FSE and intron retention (Extended Data Fig. 2b, c). We next tested whether the *UNC13A* intron retention and CE events co-occurred in transcripts. Using targeted long-read sequencing, we determined that although co-regulated, *UNC13A* CE and intron retention occurred largely independently from each other (Fig. 1l, j; Extended Data Fig. 2d, e).

UNC13A is downregulated on TDP-43 knockdown

Next, we examined whether incorrect splicing of *UNC13A* and *UNC13B* affected transcript levels in neurons and neuron-like cells. TDP-43 knockdown significantly reduced *UNC13A* RNA abundance in the three experiments with the highest levels of cryptic splicing (false discovery rate (FDR) < 0.0001; Extended Data Figs. 1h, 3a). Similarly, *UNC13B* RNA was significantly downregulated in four datasets (FDR < 0.0001) (Extended Data Fig. 3b). We confirmed these results by quantitative

PCR (qPCR) in *i*³Neurons, and SH-SY5Y and SK-N-DZ cell lines (Extended Data Figs. 1d, e, 3c, d). The number of ribosome footprints aligning to *UNC13A* and *UNC13B* was also reduced after TDP-43 knockdown (Fig. 2a, Extended Data Fig. 3e, Supplementary Data 3; FDR < 0.05). Notably, TDP-43 knockdown decreased expression of *UNC13A* and *UNC13B* at the protein level in a dose-dependent manner, as assessed by quantitative proteomics (Fig. 2b).

To assess the relation between TDP-43 reduction and *UNC13* splicing, RNA and protein levels, we assayed SH-SY5Y cells with increasing amounts of TDP-43 knockdown. We found that changes in *UNC13A* paralleled those of TDP-43, whereas *UNC13B* levels were less affected (Fig. 2c, Extended Data Fig. 3f, Supplementary Fig. 1). *UNC13A* CE inclusion and intron retention increased on TDP-43 knockdown, with the CE being detected only after more than 50% TDP-43 loss, whereas *UNC13B* FSE and intron retention were not robustly detected until more than 90% of TDP-43 expression was lost (Fig. 2c, Extended Data Fig. 3g).

To assess whether the amount of *UNC13A* CE expression was underestimated owing to efficient transcript degradation, we investigated whether it promoted NMD, as predicted by the presence of a premature termination codon. Knockdown of the key NMD factor *UPF1* or cycloheximide (CHX) treatment—which stalls translation and impairs NMD—increased the amount of *UNC13A* CE and *UNC13B* FSE, which also leads to a PTC at the beginning of exon 11, confirming that both *UNC13A* and *UNC13B* were targeted by NMD (Fig. 2d, Extended Data Fig. 3h, i). Conversely, CHX treatment and *UPF1* knockdown did not alter levels of the aberrant *STMN2* transcript, which was not predicted to undergo NMD (Fig. 2d, Extended Data Fig. 3h). Of note, CHX treatment of SH-SY5Y cells with the least TDP-43 knockdown (Fig. 2c) enabled detection of the *UNC13A* CE, supporting the notion that its occurrence may be underestimated owing to efficient degradation (Extended Data Fig. 3j, k).

Together, these data suggest that TDP-43 has an essential role in ensuring the correct pre-mRNA splicing of *UNC13A* and *UNC13B*, thereby maintaining normal expression of these key presynaptic proteins.

UNC13A cryptic exon in patient neurons

To test whether the *UNC13A* CE could be detected in tissues from patients affected by TDP-43 pathology, we first analysed RNA-seq data from neuronal nuclei sorted from frontal cortices of patients with ALS-FTLD²³. We compared the levels of *UNC13A* CE to the levels of a CE in *STMN2* known to be regulated by TDP-43. Both *STMN2* and *UNC13A* CEs were found exclusively in TDP-43-depleted nuclei. Although the lack of NMD activity in the nucleus means that the nuclear splicing ratio may not reflect that of the whole cell, in some cases, the *UNC13A* CE percent spliced in (PSI (ψ)) reached 100% (Fig. 3a). This suggests that there is a substantial loss of *UNC13A* expression in the subpopulation of neurons with TDP-43 pathology in human patients with ALS-FTLD.

Next, we quantified *UNC13A* CE inclusion in bulk RNA-seq data from the New York Genome Center (NYGC) ALS Consortium, which contains 1,349 brain and spinal cord tissues from a total of 377 individuals, including those with ALS or FTLD and controls. The *UNC13A* CE was detected exclusively in tissues from individuals with FTLD-TDP and ALS-TDP (89% and 38% of individuals, respectively), and not in individuals with non-TDP ALS (caused by *SOD1* and *FUS* mutations), FTLD associated with TAU (FTLD-TAU), FTLD associated with FUS (FTLD-FUS) or controls. There were no systematic differences across tissues between controls and non-TDP ALS or FTLD and ALS-TDP or FTLD-TDP in confounding factors such as library depth, RNA integrity number or cellular composition, which could explain the *UNC13A* CE specificity (Extended Data Fig. 4a–d). The lower detection rate in ALS compared with FTLD is possibly owing to the lower expression of *UNC13A* in the spinal cord (Extended Data Fig. 4a), although differences in NMD efficiency between cortical and spinal regions could also affect detection rate²⁴. *UNC13A* CE was more likely to be detected in




Fig. 3 | *UNC13A* CE is highly expressed in tissues from patients with ALS or FTLD and correlates with known markers of TDP-43 loss of function.

a, *UNC13A* and *STMN2* CE expression from a published dataset of frontal cortex neuronal nuclei from patients with ALS or FTLD sorted according to TDP-43 expression²³. **b**, *UNC13A* CE expression in bulk RNA-seq from the NYGC ALS Consortium data normalized by library size across disease and tissue samples. ALS cases are stratified by mutation status, FTLD cases are stratified by

pathological subtype. **c**, CE expression throughout ALS-TDP and FTLD-TDP cases across tissue, number of tissue samples in brackets. **d**, BaseScope detection of *UNC13A* CE (red foci) in FTLD-TDP (9 individuals) but not control (5 individuals) or non-TDP FTLD (FTLD-TAU) (4 individuals) frontal cortex samples and quantification of background-corrected foci frequency between groups. Scale bar, 10 μ m. Data are mean \pm s.e.m. (**b–d**); Wilcoxon test.

bulk samples that had been sequenced with 125-bp rather than 100-bp paired-end reads, but other technical factors did not systematically affect detection (Extended Data Fig. 5a–d).

UNC13A CE expression mirrored the known tissue distribution of TDP-43 aggregation and nuclear clearance²⁵: it was specific to ALS-TDP spinal cord and motor cortex, as well as FTLD-TDP frontal and temporal cortices, but was absent from the cerebellum in both disease and control states (Fig. 3b). Furthermore, although the *UNC13A* CE induces NMD (unlike the *STMN2* CE) it was detected at similar levels to the *STMN2* CE in cortical regions, whereas *STMN2* CE was more abundant in the spinal cord (Fig. 3c). Targeted long-read sequencing of *UNC13A* in FTLD frontal cortex revealed that the CE and intron retention events can co-occur but, as in SH-SY5Y cells, they are mostly detected independently (Extended Data Fig. 5e, f). Thus, pathological *UNC13A* CEs occur in vivo and are specific to neurodegenerative disease subtypes in which mislocalization and nuclear depletion of TDP-43 occurs.

We next assessed expression of the *UNC13B* FSE across the NYGC dataset. We detected no increase in the *UNC13B* FSE in pathological ALS-TDP or FTLD-TDP tissues. However, the presence throughout control and ALS or FTD brains of a shorter isoform of the CE that included the FSE, which was absent in our in vitro experiments, may mask underlying changes (Extended Data Fig. 6a–c).

We also evaluated both *UNC13A* and *UNC13B* intron retention events from bulk RNA-seq. Unlike the CE, both intron retention events were also detected in control brains, making it difficult to determine whether TDP-43 pathology increased intron retention (Extended Data Fig. 7a, b).

We next investigated whether *UNC13A* CEs could be visualized by in situ hybridization in brains from patients with FTLD, using the same

probe used for iPS cell-derived neurons. We detected red foci in cortical neurons at a significantly higher frequency in FTLD-TDP relative to both neurologically normal controls (Kruskal–Wallis test, $P = 0.021$) and non-TDP FTLD (FTLD-TAU) ($P = 0.010$) (Fig. 3d).

To assess whether *UNC13A* CE levels in bulk tissue were related to the level of TDP-43 proteinopathy, we used the *STMN2* CE PSI as a proxy. The PSI of *STMN2* CE correlates with the cryptic PSI of other well-known TDP-43 induced CEs, such as those in *RAP1GAP* and *PFKP*^{7,14} (Extended Data Fig. 7c, d) and correlates with the amount of phosphorylated TDP-43 in patient samples¹⁰. As expected, across the NYGC ALS Consortium samples we observed a significant positive correlation between the level of *STMN2* CE PSI and *UNC13A* CE PSI across the NYGC ALS Consortium samples ($\rho = 0.56$, $P = 2.9 \times 10^{-7}$, $n = 72$ cortical samples) (Extended Data Fig. 7e).

Collectively, our analysis reveals a strong relationship between TDP-43 pathology and the level of *UNC13A* CE, supporting a model with direct regulation of *UNC13A* mRNA splicing by TDP-43.

UNC13A risk SNPs exacerbate cryptic splicing

To test whether the ALS–FTD risk SNPs in *UNC13A* promote cryptic splicing, thereby explaining their link to disease, we assessed *UNC13A* CE levels across different genotypes. We found significantly increased *UNC13A* CE in cases homozygous for CE rs12973192 (G) and intronic rs12608932 (C) SNPs ($P = 0.028$, Wilcoxon test) (Extended Data Fig. 8a, Supplementary Table 4). To ensure that this was not owing to more severe TDP-43 loss of function in these samples, we normalized *UNC13A* CE by the level of *STMN2* cryptic splicing, a well-established product of TDP-43 loss of function. Again, we found significantly increased *UNC13A*




Fig. 4 | *UNC13A* ALS and FTD risk variants enhance *UNC13A* CE splicing in patients and in vitro by altering TDP-43 pre-mRNA binding. **a, Ratio of *UNC13A* and *STMN2* CE Ψ in ALS-TDP and FTLD-TDP cortex, split by genotype for *UNC13A* risk alleles. In box plots, the centre line shows the median, box edges delineate 25th and 75th percentiles and Tukey whiskers are plotted. **b**, Unique cDNAs from targeted RNA-seq in ten patients with FTLD-TDP who are heterozygous for the risk SNP within the *UNC13A* cryptic exon. Single-tailed binomial tests. Patients 1, 5 and 7 carry the C9orf72 hexanucleotide repeat. **c**, Schematic of *UNC13A* minigenes containing exon 20, intron 20 and exon 21 and combinations of *UNC13A* alleles. **d, e**, Representative image (**d**) and quantification (**e**) of RT-PCR products from *UNC13A* minigenes in SH-SY5Y cells with or without TDP-43 knockdown. Data are mean \pm s.e.m. Each variant was compared with the healthy minigene binding with which it was co-transfected and**

results were compared with an unpaired *t*-test ($n = 3$ biological replicates). **f**, TDP-43 iCLIP of SH-SY5Y cells containing 2R and 2H minigenes. Top, average crosslink density. Middle, average density change 2R for -2H (20-nt rolling window, units are crosslinks per 1,000). Bottom, predicted TDP-43 binding footprints (UGNUG motif). **g**, Average change in E-value (measure of binding enrichment) across proteins for heptamers containing risk or healthy CE SNP alleles. TDP-43 is indicated in red. **h**, Binding affinities between TDP-43 and 14-nt RNA containing the CE ($n = 4$) or intronic ($n = 3$) healthy or risk sequences measured by isothermal titration calorimetry. Data are mean \pm s.d.; two-sample *t*-test. **i, j**, Representative image (**i**) and quantification (**j**) of RT-PCR products from *UNC13A* minigenes with mutated UGNUG TDP-43 binding motifs as shown in **f**. Data are mean \pm s.e.m.; $n = 3$ biological replicates; statistical analysis as in (**d, e**).

CE in cases with homozygous risk variants ($P < 0.001$, Wilcoxon test) (Fig. 4a, Extended Data Fig. 8b). Next, we performed targeted RNA-seq on *UNC13A* CE from temporal cortices of ten FTLD-TDP patients who

were heterozygous in the risk allele and four controls (Supplementary Table 5). There was no detection of the CE in the control samples, and in the patient samples we detected significant biases towards reads

containing the risk allele ($P < 0.05$, single-tailed binomial test) in six samples, with a seventh sample approaching significance (Fig. 4b), suggesting that the two ALS- and FTLN-linked variants promote cryptic splicing in vivo.

To directly assess whether the risk SNPs increase CE inclusion, we performed minigenes experiments. Using two minigenes containing *UNC13A* exon 20, intron 20 and exon 21, with and without the two ALS- and FTLN-linked variants, we determined that the risk variants enhanced CE upon TDP-43 loss (Extended Data Fig. 8c). To examine whether the CE SNP, intronic SNP or short tandem repeat expansion rs56041637—which is in linkage disequilibrium with the two SNPs²⁶—are responsible for promoting the CE inclusion, we generated minigenes featuring different combinations of these genomic variants (Fig. 4c). Using quantitative analysis of RT-PCR products, we found that both the CE SNP and, to a lesser extent, the intronic SNP independently promoted CE inclusion, with the highest overall levels detected for the 2R minigene (Fig. 4d, e, Extended Data Fig. 8d).

TDP-43 can both inhibit and promote splicing by binding to pre-mRNA. We performed TDP-43 iCLIP in HEK 293T cells expressing either the 2R or the 2H minigene to fine map TDP-43 binding to *UNC13A* intron 20 and investigate whether the risk SNPs have an effect on this interaction. In agreement with our iCLIP data of endogenous *UNC13A* in SH-SY5Y cells (Extended Data Fig. 2b), we observed an enrichment of crosslinks within the approximately 800-nucleotide UG-rich region containing both SNPs in intron 20 (Fig. 4f). When comparing 2R with 2H, the largest fractional changes were near each SNP (Extended Data Fig. 8e). We detected a 21% decrease in total TDP-43 crosslinks centred around the CE SNP and a 73% increase upstream of the intronic SNP (Fig. 4f, Extended Data Fig. 8f; 50-nucleotide windows). These data suggest these two disease-risk SNPs distort the pattern of TDP-43-RNA interactions, decreasing TDP-43 binding near the CE donor splice site.

To explore whether these two SNPs directly influence TDP-43 binding, we analysed a dataset of in vitro RNA heptamer-RBP binding enrichments. We examined the effect of the SNPs on relative RBP enrichment²⁷ by comparing healthy versus risk SNP-containing heptamers. When investigating which RBPs were most affected in their RNA binding enrichment by the CE risk SNP, TDP-43 had the third largest decrease of any RBP, with only two non-mammalian RBPs showing a larger decrease (Fig. 4g, Extended Data Fig. 8g). The intronic SNP did not strongly affect TDP-43 binding, although data was only available for 2 out of 7 possible heptamers (Extended Data Fig. 8h, i). To verify that the CE SNP directly inhibited TDP-43 binding, we performed isothermal titration calorimetry using recombinant TDP-43 and short RNAs. We observed nanomolar binding affinity in all cases, with an increased dissociation constant (K_d) (lower binding affinity) for the CE SNP region ($P = 0.023$, two-sample t -test) and a trend of decreasing K_d for the intronic SNP region ($P = 0.052$) when the risk variants were present (Fig. 4h, Extended Data Fig. 9a–d, Supplementary Data 4). Last, to test whether TDP-43 binding to the CE SNP region is critical for CE repression, we mutated the UGNNUG TDP-43-binding motif in this region, leading to significantly increased CE inclusion (Fig. 4i, j, Extended Data Fig. 9e). Together these data suggest that the risk SNPs modulate TDP-43 binding, in part via direct changes in binding affinity, exacerbating *UNC13A* CE inclusion.

Discussion

Our results support a model in which *UNC13A* SNPs and TDP-43 loss synergistically drive cryptic exon inclusion in *UNC13A* transcripts, thereby reducing expression of a synaptic gene that is critical for normal neuronal function.

In this model, when nuclear TDP-43 levels are normal in healthy individuals, TDP-43 binds efficiently to *UNC13A* pre-mRNA, even in the presence of risk SNPs, thus preventing CE splicing. Conversely, severe nuclear depletion of TDP-43 in end-stage disease induces CE inclusion

in all cases. However, in the setting of partial TDP-43 loss that occurs early in degenerating neurons, risk-associated intronic and CE risk SNPs alter TDP-43 binding to *UNC13A* pre-mRNA, exacerbating CE inclusion in these transcripts. The ensuing loss of *UNC13A* protein—which is critical for normal synaptic activity—at earlier disease stages may explain the associated risk effect of these SNPs. Notably, we found that both risk alleles for these SNPs independently and additively promoted cryptic splicing in vitro. Further, when the two variants are not co-inherited, as seen in individuals from east Asia with ALS, an attenuated effect is observed¹⁹. A similar phenomenon, in which SNP pairs both contribute to risk, has been widely studied at the APOE locus in Alzheimer's disease²⁸. Clarification of single versus additive effects of co-inherited SNPs regarding effects on CE inclusion, as well as contributions of other RBPs, will require future investigation.

UNC13 family proteins are highly conserved across metazoans and are essential for calcium-triggered synaptic vesicle release²⁹. In mice, single knockout of *Unc13a* blocks action potential-induced neurotransmitter release from the majority of glutamatergic hippocampal synapses³⁰. Double knockout of *Unc13a* and *Unc13b* inhibits both excitatory and inhibitory synaptic transmission in hippocampal neurons and greatly impairs transmission at neuromuscular junctions^{31,32}. In TDP-43-depleted neuronal nuclei derived from patients with ALS or FTLN, which reflect transcript expression before NMD, the *UNC13A* CE is present in up to 100% of transcripts, suggesting that expression of functional *UNC13A* is markedly reduced, which could affect normal synaptic transmission.

TDP-43 loss induces hundreds of splicing changes, several of which have also been detected in brains of patients with ALS or FTLN. However, it has remained unclear whether these events—even those that occur in essential neuronal genes—contribute to disease pathogenesis. The fact that genetic variation modulating *UNC13A* CE levels influences the rate of ALS progression strongly supports the role of *UNC13A* downregulation as an important effector of neurotoxicity mediated by TDP-43 loss. The *UNC13A* CE is thus a promising target for therapies that modulate splicing, potentially applicable to 97% of ALS cases and approximately half of FTD cases. These findings are also of interest to other neurodegenerative diseases—such as Alzheimer's disease, Parkinson's disease and chronic traumatic encephalopathy—in which TDP-43 depletion occurs in a substantial fraction of cases.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-022-04436-3>.

- van Es, M. A. et al. Genome-wide association study identifies 19p13.3 (*UNC13A*) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. *Nat. Genet.* **41**, 1083–1087 (2009).
- Pottier, C. et al. Genome-wide analyses as part of the international FTLN-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLN. *Acta Neuropathol.* **137**, 879–899 (2019).
- Diekstra, F. P. et al. C9orf72 and *UNC13A* are shared risk loci for ALS and FTD: a genome-wide meta-analysis. *Ann. Neurol.* **76**, 120–133 (2014).
- Tan, R. H., Ke, Y. D., Ittner, L. M. & Halliday, G. M. ALS/FTLN: experimental models and reality. *Acta Neuropathol.* **133**, 177–196 (2017).
- Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* **314**, 130–133 (2006).
- Ji, A.-L., Zhang, X., Chen, W.-W. & Huang, W.-J. Genetics insight into the amyotrophic lateral sclerosis/frontotemporal dementia spectrum. *J. Med. Genet.* **54**, 145–154 (2017).
- Ling, J. P., Pletnikova, O., Troncoso, J. C. & Wong, P. C. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. *Science* **349**, 650–655 (2015).
- Melamed, Z. et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. *Nat. Neurosci.* **22**, 180–190 (2019).
- Klim, J. R. et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. *Nat. Neurosci.* **22**, 167–179 (2019).
- Prudencio, M. et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. *J. Clin. Invest.* **130**, 6080–6092 (2020).

11. Fernandopulle, M. S. et al. Transcription factor-mediated differentiation of human iPSCs into neurons. *Curr. Protoc. Cell Biol.* **79**, e51 (2018).
12. Tian, R. et al. CRISPR interference-based platform for multimodal genetic screens in human iPSC-derived Neurons. *Neuron* **104**, 239–255.e12 (2019).
13. Wang, C. et al. Scalable production of iPSC-derived human neurons to identify Tau-lowering compounds by high-content screening. *Stem Cell Rep.* **9**, 1221–1233 (2017).
14. Humphrey, J., Emmett, W., Fratta, P., Isaacs, A. M. & Plagnol, V. Quantitative analysis of cryptic splicing associated with TDP-43 depletion. *BMC Med. Genomics* **10**, 38 (2017).
15. Nicolas, A. et al. Genome-wide analyses identify *KIF5A* as a novel ALS gene. *Neuron* **97**, 1268–1283.e6 (2018).
16. Martin, A. R. et al. PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. *Nat. Genet.* **51**, 1560–1565 (2019).
17. Diekstra, F. P. et al. *UNC13A* is a modifier of survival in amyotrophic lateral sclerosis. *Neurobiol. Aging* **33**, 630.e3–8 (2012).
18. Placek, K. et al. *UNC13A* polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. *Neurobiol. Aging* **73**, 190–199 (2019).
19. Yang, B. et al. *UNC13A* variant rs12608932 is associated with increased risk of amyotrophic lateral sclerosis and reduced patient survival: a meta-analysis. *Neurol. Sci.* **40**, 2293–2302 (2019).
20. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, 434–443 (2020).
21. Appocher, C. et al. Major hnRNP proteins act as general TDP-43 functional modifiers both in *Drosophila* and human neuronal cells. *Nucleic Acids Res.* **45**, 8026–8045 (2017).
22. Tollervey, J. R. et al. Characterising the RNA targets and position-dependent splicing regulation by TDP-43; implications for neurodegenerative diseases. *Nat. Neurosci.* **14**, 452–458 (2011).
23. Liu, E. Y. et al. Loss of nuclear TDP-43 is associated with decondensation of LINE retrotransposons. *Cell Rep.* **27**, 1409–1421.e6 (2019).
24. Zetoune, A. B. et al. Comparison of nonsense-mediated mRNA decay efficiency in various murine tissues. *BMC Genet.* **9**, 83 (2008).
25. Couratier, P., Corcia, P., Lautrette, G., Nicol, M. & Marin, B. ALS and frontotemporal dementia belong to a common disease spectrum. *Rev. Neurol.* **173**, 273–279 (2017).
26. Ma, X. R. et al. TDP-43 represses cryptic exon inclusion in the FTD-ALS gene *UNC13A*. *Nature* <https://doi.org/10.1038/s41586-022-04424-7> (2022).
27. Ray, D. et al. A compendium of RNA-binding motifs for decoding gene regulation. *Nature* **499**, 172–177 (2013).
28. Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921–923 (1993).
29. Dittman, J. S. *Unc13*: a multifunctional synaptic marvel. *Curr. Opin. Neurobiol.* **57**, 17–25 (2019).
30. Augustin, I., Rosenmund, C., Südhof, T. C. & Brose, N. *Munc13-1* is essential for fusion competence of glutamatergic synaptic vesicles. *Nature* **400**, 457–461 (1999).
31. Varoqueaux, F. et al. Total arrest of spontaneous and evoked synaptic transmission but normal synaptogenesis in the absence of *Munc13*-mediated vesicle priming. *Proc. Natl Acad. Sci. USA* **99**, 9037–9042 (2002).
32. Varoqueaux, F., Sons, M. S., Plomp, J. J. & Brose, N. Aberrant morphology and residual transmitter release at the *Munc13*-deficient mouse neuromuscular synapse. *Mol. Cell. Biol.* **25**, 5973–5984 (2005).
33. Vaquero-Garcia, J. et al. A new view of transcriptome complexity and regulation through the lens of local splicing variations. *eLife* **5**, e11752 (2016).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

Article

NYGC ALS Consortium

Hemali Phatnani⁷, Justin Kwan²⁰, Dhruv Sareen^{21,22}, James R. Broach²³, Zachary Simmons²⁴, Ximena Arcila-Londono²⁵, Edward B. Lee²⁶, Viviana M. Van Deerlin²⁶, Neil A. Shneider²⁷, Ernest Fraenkel²⁸, Lyle W. Ostrow²⁹, Frank Baas^{30,31}, Noah Zaitlen³², James D. Berry^{33,34}, Andrea Malaspina^{35,36,37}, Pietro Fratta¹, Gregory A. Cox³⁸, Leslie M. Thompson^{39,40}, Steve Finkbeiner⁴¹, Efthimios Dardiotis⁴², Timothy M. Miller⁴³, Siddharthan Chandran⁴⁴, Suvankar Pal⁴⁴, Eran Hornstein⁴⁵, Daniel J. MacGowan⁴⁶, Terry Heiman-Patterson⁴⁷, Molly G. Hammell⁴⁸, Nikolaos A. Patsopoulos⁴⁹, Oleg Butovsky⁴⁹, Joshua Dubnau⁵⁰, Avindra Nath⁵¹, Robert Bowser^{52,53}, Matthew Harms⁵⁴, Eleonora Aronica⁵⁵, Mary Poss⁵⁶, Jennifer Phillips-Cremins⁵⁷, John Craty^{13,14,58}, Nazem Atassi⁵⁹, Dale J. Lange^{60,61}, Darius J. Adams^{62,63}, Leonidas Stefanis^{64,65}, Marc Gotkine⁶⁶, Robert H. Baloh^{67,68}, Suma Babu³⁴, Towfique Raj^{13,14,15,16}, Sabrina Paganoni⁶⁹, Ophir Shalem^{70,71}, Colin Smith^{72,73}, Bin Zhang⁷⁴, Brent Harris⁷⁵, Iris Broce⁷⁶, Vivian Drory⁷⁷, John Ravits⁷⁸, Corey McMillan⁷⁹, Vilas Menon⁸⁰, Lani Wu⁸¹, Steven Altschuler⁸¹, Yossef Lerner⁸², Rita Sattler⁸³, Kendall Van Keuren-Jensen⁸⁴, Orit Rozenblatt-Rosen⁸⁵, Kerstin Lindblad-Toh⁸⁵, Katharine Nicholson⁸⁶, Peter Gregersen⁸⁷, Jeong-Ho Lee⁸⁸, Sulev Kokos⁸⁹ & Stephen Muljo⁹⁰

²⁰Department of Neurology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA. ²¹Cedars-Sinai Department of Biomedical Sciences, Board of Governors Regenerative Medicine Institute and Brain Program, Cedars-Sinai Medical Center, University of California, Los Angeles, CA, USA. ²²Department of Medicine, University of California, Los Angeles, CA, USA. ²³Department of Biochemistry and Molecular Biology, Penn State Institute for Personalized Medicine, The Pennsylvania State University, Hershey, PA, USA. ²⁴Department of Neurology, The Pennsylvania State University, Hershey, PA, USA. ²⁵Department of Neurology, Henry Ford Health System, Detroit, MI, USA. ²⁶Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ²⁷Department of Neurology, Center for Motor Neuron Biology and Disease, Institute for Genomic Medicine, Columbia University, New York, NY, USA. ²⁸Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. ²⁹Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA. ³⁰Department of Neurogenetics, Academic Medical Centre, Amsterdam, The Netherlands. ³¹Leiden University Medical Center, Leiden, The Netherlands. ³²Department of Medicine, Lung Biology Center, University of California, San Francisco, CA, USA. ³³ALS Multidisciplinary Clinic, Neuromuscular Division, Department of Neurology, Harvard Medical School, Boston, MA, USA. ³⁴Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, MA, USA. ³⁵Centre for Neuroscience and Trauma, Blizard Institute, Barts, Queen Mary University of London, London, UK. ³⁶The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. ³⁷Department of Neurology, Basildon University Hospital, Basildon, UK. ³⁸The Jackson Laboratory, Bar Harbor, ME, USA. ³⁹Department of Psychiatry and Human Behavior, Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA, USA. ⁴⁰Department of Neurobiology and Behavior, School of Biological Sciences, University of California, Irvine, CA, USA. ⁴¹Taube/Koret Center for Neurodegenerative Disease Research, Roddenberry Center for Stem Cell Biology and Medicine, Gladstone Institute, San Francisco, CA, USA. ⁴²Department of Neurology and Sensory Organs, University of Thessaly, Thessaly, Greece. ⁴³Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA. ⁴⁴Centre for Clinical Brain Sciences, Anne Rowling Regenerative Neurology Clinic, Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK. ⁴⁵Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel. ⁴⁶Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁴⁷Center for Neurodegenerative Disorders, Department of Neurology, the Lewis Katz School

of Medicine, Temple University, Philadelphia, PA, USA. ⁴⁸Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA. ⁴⁹Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ⁵⁰Department of Anesthesiology, Stony Brook University, Stony Brook, NY, USA. ⁵¹Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA. ⁵²Department of Neurology, Barrow Neurological Institute, St Joseph's Hospital, Phoenix, AZ, USA. ⁵³Medical Center, Department of Neurobiology, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, AZ, USA. ⁵⁴Department of Neurology, Division of Neuromuscular Medicine, Columbia University, New York, NY, USA. ⁵⁵Department of Neuropathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. ⁵⁶Department of Biology and Veterinary and Biomedical Sciences, The Pennsylvania State University, University Park, PA, USA. ⁵⁷New York Stem Cell Foundation, Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, PA, USA. ⁵⁸Department of Pathology, Fishberg Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁵⁹Department of Neurology, Harvard Medical School, Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, MA, USA. ⁶⁰Department of Neurology, Hospital for Special Surgery, New York, NY, USA. ⁶¹Weill Cornell Medical Center, New York, NY, USA. ⁶²Medical Genetics, Atlantic Health System, Morristown Medical Center, Morristown, NJ, USA. ⁶³Overlook Medical Center, Summit, NJ, USA. ⁶⁴Center of Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece. ⁶⁵1st Department of Neurology, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. ⁶⁶Neuromuscular/EMG service and ALS/Motor Neuron Disease Clinic, Hebrew University-Hadassah Medical Center, Jerusalem, Israel. ⁶⁷Board of Governors Regenerative Medicine Institute, Los Angeles, CA, USA. ⁶⁸Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. ⁶⁹Harvard Medical School, Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Boston, MA, USA. ⁷⁰Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. ⁷¹Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ⁷²Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. ⁷³Euan MacDonald Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK. ⁷⁴Department of Genetics and Genomic Sciences, Icahn Institute of Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁷⁵Department of Neuropathology, Georgetown Brain Bank, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. ⁷⁶Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA. ⁷⁷Neuromuscular Diseases Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. ⁷⁸Department of Neuroscience, University of California San Diego, La Jolla, CA, USA. ⁷⁹Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. ⁸⁰Department of Neurology, Columbia University Medical Center, New York, NY, USA. ⁸¹Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA. ⁸²Hadassah Hebrew University, Jerusalem, Israel. ⁸³Department of Translational Neuroscience, Barrow Neurological Institute, Phoenix, AZ, USA. ⁸⁴The Translational Genomics Research Institute (TGen), Phoenix, AZ, USA. ⁸⁵Broad Institute, Cambridge, MA, USA. ⁸⁶Massachusetts General Hospital, Boston, MA, USA. ⁸⁷Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA. ⁸⁸Korea Advanced Institute of Science and Technology (KAIST), Daejeon, South Korea. ⁸⁹Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia. ⁹⁰Integrative Immunobiology Section, National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD, USA.

Methods

Human iPS cell culture

All policies of the NIH Intramural research program were followed for the procurement and use of iPS cells. For most studies, the iPS cells used were from the WTC11 line, derived from a healthy 30-year-old male, and obtained from the Coriell cell repository. Informed consent was obtained from the donor. We confirmed the WTC11 line contained no ALS-FTD mutations in the ALS and FTD risk genes in Supplementary Table 1. For key experiments, an independent line was used, NCRM5. NCRM5 was derived from umbilical cord blood from NIH Center for Regenerative Medicine (CRM), Bethesda, MD, USA. Informed consent was obtained from the donor. All culture procedures were conducted as previously¹¹. In brief, iPS cells were grown on tissue culture dishes coated with human embryonic stem cell-qualified Matrigel (Corning, catalogue no. 354277). They were maintained in Essential 8 Medium (E8; Thermo Fisher Scientific, catalogue (cat.) no. A1517001) supplemented with 10 μ M ROCK inhibitor (RI; Y-27632; Selleckchem, cat. no. S1049) in a 37 °C, 5% CO₂ incubator. Medium was replaced every 1–2 days as needed. Cells were passaged with accutase (Life Technologies, cat. no. A1110501), 5–10 min treatment at 37 °C. Accutase was removed and cells were washed with PBS before re-plating. Following dissociation, cells were plated in E8 media supplemented with 10 μ M RI to promote survival. RI was removed once cells grew into colonies of 5–10 cells.

The following cell line and DNA samples were obtained from the NIGMS Human Genetic Cell Repository at the Coriell Institute for Medical Research: GM25256.

Data

Publicly available data were obtained from the Gene Expression Omnibus (GEO): iPS cell MNs⁹, GSE121569; SK-N-DZ^b, GSE97262; FACS-sorted frontal cortex neuronal nuclei, GSE126543; Riboseq, E-MTAB-10235; targeted RNA-seq, E-MTAB-10237; minigene TDP-43 iCLIP, E-MTAB-10297; SH-SY5Y TDP-43 iCLIP, E-MTAB-11243; and *UNC13A*-targeted nanopore, E-MTAB-11244.

CRISPRi knockdown in human iPS cells

The human iPS cells used in this study were previously engineered^{11,13} to express mouse or human neurogenin-2 (NGN2) under a doxycycline-inducible promoter, as well as an enzymatically dead Cas9 (+/- CAG-dCas9-BFP-KRAB)¹². For WTC11 these were integrated at the AAVS1 safe harbour and the CLYBL promoter safe harbour respectively, while for NCRM5, these were both integrated at the CLYBL promoter safe harbour.

To achieve knockdown, sgRNAs targeting either *TARDBP*/TDP-43, *UPFI* or a non-targeting control guide were delivered to iPS cells by lentiviral transduction. To make the virus, Lenti-X human embryonic kidney (HEK) cells were transfected with the sgRNA plasmids using Lipofectamine 3000 (Life Technologies, cat. no. L3000150), then cultured for 2–3 days in the following media: DMEM, high glucose GlutaMAX Supplement media (Life Technologies, cat. no. 10566024) with 10% FBS (Sigma, cat. no. TMS-013-B), supplemented with viral boost reagent (ALSTEM, cat. no. VB100). Virus was then concentrated from the media 1:10 in PBS using Lenti-X concentrator (Takara Bio, cat. no. 631231), aliquoted and stored at -80 °C for future use.

The sgRNAs were cloned into either pU6-sgRNA EF1 α -puro-T2A-BFP vector^{12,37} (gift from J. Weissman; Addgene 60955) or a modified version containing a human U6 promoter, a blasticidin (Bsd) resistance gene, and eGFP. sgRNA sequences were as follows: non-targeting control: GTCCACCCTTATCTAGGCTA, *UPFI*: GGCCAGACGCAGACGCC CCC, and *TARDBP*: GGG AAGTCAGCCGTGAGACC (strong guide), and GCGGCCTAGCGGGT GAGTCG (weaker guide). The stronger *TARDBP* guide was used in all cases unless otherwise stated.

Virus was delivered to iPS cells in suspension following an accutase split. Cells were plated and cultured overnight. The following morning, cells

were washed with PBS and media was changed to E8 or E8+RI depending on cell density. Two days after lentiviral delivery, cells were selected overnight with either puromycin (10 μ g ml⁻¹) or blasticidin (50–100 μ g ml⁻¹). iPS cells were then expanded 1–2 days before initiating neuronal differentiation. Knockdown efficiency was tested at iPS cell and neuronal stages using immunofluorescence, qPCR and observed in RNA-seq data.

iPS cell-derived i³Neuron differentiation and culture

To initiate neuronal differentiation, 20–25 million iPS cells per 15 cm plate were individualized using accutase on day 0 and re-plated onto Matrigel-coated tissue culture dishes in N2 differentiation media containing: knockout DMEM/F12 media (Life Technologies Corporation, cat. no. 12660012) with N2 supplement (Life Technologies Corporation, cat. no. 17502048), 1 \times GlutaMAX (ThermoFisher Scientific, cat. no. 35050061), 1 \times MEM nonessential amino acids (NEAA) (ThermoFisher Scientific, cat. no. 11140050), 10 μ M ROCK inhibitor (Y-27632; Selleckchem, cat. no. S1049) and 2 μ g ml⁻¹ doxycycline (Clontech, cat. no. 631311). Media was changed daily during this stage.

On day 3 pre-neuron cells were replated onto dishes coated with freshly made poly-L-ornithine (PLO; 0.1 mg ml⁻¹; Sigma, cat. no. P3655-10MG), either 96-well plates (50,000 per well), 6-well dishes (2 million per well), or 15 cm dishes (45 million per plate), in i³Neuron Culture Media: Brain-Phys media (Stemcell Technologies, cat. no. 05790) supplemented with 1 \times B27 Plus Supplement (ThermoFisher Scientific, cat. no. A3582801), 10 ng ml⁻¹ BDNF (PeproTech, cat. no. 450-02), 10 ng ml⁻¹ NT-3 (PeproTech, cat. no. 450-03), 1 μ g ml⁻¹ mouse laminin (Sigma, cat. no. L2020-1MG), and 2 μ g ml⁻¹ doxycycline (Clontech, cat. no. 631311). i³Neurons were then fed three times a week by half media changes. i³Neurons were then collected on day 7 or 17 after the addition of doxycycline or 4 or 14 days after re-plating.

Generation of stable TDP-43-knockdown cell line

SH-SY5Y and SK-N-DZ cells were transduced with SmartVector lentivirus (V3IHSHEG_6494503) containing a doxycycline-inducible shRNA cassette for TDP-43. Transduced cells were selected with puromycin (1 μ g ml⁻¹) for one week. For doxycycline dose-response experiments, the pool of TDP-43-knockdown SH-SY5Y cells were plated as single cells and expanded to obtain a clonal population.

Depletion of TDP-43 from immortalized human cell lines

SH-SY5Y cells for RT-qPCR validations and western blots were grown in DMEM/F12 containing GlutaMAX (Thermo) supplemented with 10% FBS (Thermo). For induction of shRNA against TDP-43 cells were treated with 5 μ g ml⁻¹ doxycycline hyclate (Sigma D9891). After 3 days medium was replaced with Neurobasal (Thermo) supplemented with B27 (Thermo) to induce differentiation. After a further 7 days, cells were collected for protein or RNA. For doxycycline dose response experiments, doxycycline was used at concentrations of 12.5 ng ml⁻¹, 18.75 ng ml⁻¹, 21 ng ml⁻¹, 25 ng ml⁻¹, and 75 ng ml⁻¹. SH-SY5Y and SK-N-DZ cells for RNA-seq experiments were treated with siRNA, as previously described²¹.

RNA sequencing, differential gene expression and splicing analysis

For RNA-seq experiments of i³Neurons, the i³Neurons were grown on 96-well dishes. For collection on day 17, media was completely removed, and wells were treated with tri-reagent (100 μ l per well) (Zymo research corporation, cat. no. R2050-1-200). Then 5 wells were pooled together for each biological replicate: control ($n = 4$); TDP-43 knockdown ($n = 3$). To isolate RNA, we used a Direct-zol RNA miniprep kit (Zymo Research Corporation, cat. no. R2052), following manufacturer's instructions including the optional DNase step. Note: one knockdown replicate did not pass RNA quality controls and so was not submitted for sequencing, resulting in a total of $n = 3$ samples for this condition. Sequencing libraries were prepared with polyA enrichment using a TruSeq Stranded mRNA Prep Kit (Illumina) and sequenced (2 \times 75 bp) on an Illumina HiSeq 2500 machine.

Article

Samples were quality trimmed using Fastp with the parameter “qualified_quality_phred: 10”, and aligned to the GRCh38 genome build using STAR (v2.7.0f)³⁸ with gene models from GENCODE v31³⁹. Gene expression was quantified using FeatureCounts⁴⁰ using gene models from GENCODE v31. Any gene which did not have an expression of at least 0.5 counts per million (CPM) in more than 2 samples was removed. For differential gene expression analysis, all samples were run in the same manner using the standard DESeq2⁴¹ workflow without additional covariates, except for the Klim MNs dataset⁹, where we included the day of differentiation. The DESeq2 median of ratios, which controls for both sequencing depth and RNA composition, was used to normalize gene counts. Differential expression was defined at a Benjamini–Hochberg false discovery rate < 0.1. Salmon (v1.5.1)⁴² using an index built from GENCODE v34³⁹ was used to assess the isoform expression of *UNC13B*. Our alignment pipeline is implemented in Snakemake version 5.5.4⁴³ and available at: https://github.com/frattalab/rna_seq_snakemake.

STAR aligned BAMs were used as input to MAJIQ (v2.1)³³ for differential splicing analysis using the GRCh38 reference genome. A threshold of 10% $\Delta\psi$ was used for calling the probability of significant change between groups. The results of the deltaPSI module were then parsed using custom R scripts to obtain ψ and probability of change for each junction. Cryptic splicing was defined as junctions with $\psi < 5\%$ in control samples, $\Delta\psi > 10\%$, and the junction was unannotated in GENCODE v31. Our splicing pipeline is implemented in Snakemake version 5.5.4 and available at: <https://github.com/frattalab/splicing>.

Counts for specific junctions were tallied by parsing the STAR splice junction output tables using bedtools⁴⁴. Splice junction parsing pipeline is implemented in Snakemake version 5.5.4 and available at: https://github.com/frattalab/bedops_parse_star_junctions. ψ was evaluated using coordinates in Supplementary Table 6:

$$\psi = \frac{\text{Inclusion reads}}{\text{Inclusion reads} + \text{exclusion reads}}$$

Intron retention was assessed using IRFinder³⁶ with gene models from GENCODE v31.

Analysis of published iCLIP data

Cross-linked read files from TDP-43 iCLIP experiments in SH-SY5Y and human neuronal stem cells²² were processed using iCount v2.0.1.dev implemented in Snakemake version 5.5.4, available at https://github.com/frattalab/pipeline_icip. Sites of cross-linked reads from all replicates were merged into a single file using iCount group command. Significant positions of cross-link read density with respect to the same gene (GENCODE v34 annotations) were then identified using the iCount peaks command with default parameters.

Western blot

SH-SY5Y cells were lysed directly in the sample loading buffer (Thermo NP0008). Lysates were heated at 95 °C for 5 min with 100 mM DTT. If required lysates were passed through a QIAshredder (Qiagen) to shear DNA. Lysates were resolved on 4–12% Bis-Tris Gels (Thermo) or homemade 6% Bis-Tris gels and transferred to 0.45 μm PVDF (Millipore) membranes. After blocking with 5% milk, blots were probed with antibodies (Rb anti-UNC13A (Synaptic Systems 126 103) 1:2,000; Rb anti-UNC13B (abcam ab97924) 1:1,000; Rat anti-Tubulin (abcam ab6161 clone YOL1/34) 1:5,000, Mouse anti-TDP-43 (abcam ab104223 clone 3H8) 1:5,000) for 2 h at room temperature. After washing, blots were probed with HRP conjugated secondary antibodies (Goat anti-Rabbit HRP (Bio-Rad 1706515) 1:10,000; Goat anti-Mouse HRP (Bio-Rad 1706516) 1:10,000; Rabbit anti-Rat HRP (Dako P0450) 1:10,000) and developed with Chemiluminescent substrate (Merck Millipore WBKLS0500) on a ChemiDoc Imaging System (Bio-Rad). Band intensity was measured with ImageJ (NIH version 2.0.0-rc-69).

RT-qPCR

RNA was extracted from SH-SY5Y and SK-N-DZ cells with a RNeasy kit (Qiagen) or from i³Neurons on day 7 after the initiation of differentiation using a Direct-zol RNA miniprep kit (Zymo Research R2052) following the manufacturer's protocol including the on-column DNA digestion step. RNA concentrations were measured by Nanodrop and 500–1,000 ng of RNA was used for reverse transcription. First strand cDNA synthesis was performed with SSIV (Thermo 18090050), RevertAid (Thermo K1622) or High-Capacity cDNA Reverse Transcription Kit (Thermo 4368814) using random hexamer primers and following the manufacturer's protocol including all optional steps. Gene expression analysis was performed by qPCR using Taqman Multiplex Universal Master Mix (Thermo 4461882) or Taqman Universal PCR Master Mix (Thermo 4304437) and TaqMan assays (UNC13A-Fam Hs00392638_m1, UNC13B-Fam Hs01066405_m1, TDP-43-Vic Hs00606522_m1, GAPDH-Jun assay 4485713, TDP-43-FAM Hs00606522_m1, UPF1-FAM Hs00161289_m1, HPRT1-FAM Hs02800695_m1) on a QuantStudio 5 or a QuantStudio 6 Flex Real-Time PCR system (Applied Biosystems) and quantified using the $\Delta\Delta C_t$ method⁴⁵.

RT-PCR

RNA extraction and cDNA synthesis was performed as described under ‘RT-qPCR’. *UNC13A* CE was amplified with a forward primer in exon 20 (5'-CAAGCGAAGTACAAATCTGCCGTGTCG-3') and reverse primer in exon 21 (5'-GGCATCGTCACCCCTGGCATCTGG-3'). *UNC13A* intron retention was amplified with a forward primer in exon 30 (5'-ATGCCCTATTCTCCTGCTCC-3') and a reverse primer that spans the exon 32–33 junction (5'-CATCCAGCTCCTTTCTCC-3'). *UNC13B* FSE was amplified with forward primer (5'-TCCGAGCAGTTACCAAGTT-3') and reverse primer (5'-GCTGTCAATGCCATAGAGCC-3'). *UNC13B* intron retention was amplified with a forward primer that spans the exon 19–20 junction (5'-CAGGCCATGACGCACTTTG-3') and a reverse primer in exon 22 (5'-GATTTAAGTCCTGAAGCCGTTTC-3'). For Sanger sequencing, *UNC13A* CE was amplified with exon 19 forward primer (5'-GACATCAAATCCCCTGCGTAA-3') and exon 22 reverse primer (5'-CATTGATGTTGGCGAGCAGG-3'). Amplicons were resolved by agarose gel and the bands corresponding to the short and long form of the cryptic exon were excised and purified (NEB T1030L). The *UNC13A* exon 22 reverse primer (5'-ATACTTGGAGGAGAGGCAGG-3') was used for sequencing reactions. PCR products were resolved on a TapeStation 4200 (Agilent) and bands were quantified with TapeStation Systems Software v3.2 (Agilent).

Nonsense-mediated decay inhibition

For the SH-SY5Y experiment, 10 days after the induction of shRNA against TDP-43 with 1 $\mu\text{g ml}^{-1}$ doxycycline hyclate (Sigma D9891-1G), cells were treated either with 100 μM CHX or DMSO⁴⁶ for 6 h before collecting the RNA with a RNeasy Minikit (Qiagen). Reverse transcription was performed using RevertAid cDNA synthesis kit (Thermo), and transcript levels were quantified by qPCR (QuantStudio 5 Real-Time PCR system, Applied Biosystems) using the $\Delta\Delta C_t$ method⁴⁵. Using RefFinder (<https://www.heartcure.com.au/reffinder/>), we identified *GAPDH* as the most stable endogenous control across our conditions of interest; the forward *GAPDH* primer used was 5'-CACCAGGCTGCTTTTAAC-3', and the reverse primer was 5'-GACAAGCTTCCCGTTCTCAG-3'. Since it has been shown to undergo NMD⁴⁷, *HNRNPL* NMD transcript was used as a positive control. The *UNC13B* experiment was subsequently performed, following the same method.

For the TDP-43-UPF1 double siRNA knockdown, SH-SY5Y cells were transfected with 40 pM TDP-43 siRNA and either 40 pM control or 40 pM UPF1 siRNAs, and collected after 96 h. Similarly to our experiment with CHX, we used a qPCR approach with *GAPDH* as endogenous control and *HNRNPL* as positive control. To assess TDP-43 and UPF1 levels, we used the following primers: TDP-43 forward, 5'-GATGGTGTACTGCAAACCTTC-3';

TDP-43 reverse, 5'-CAGCTCATCCTCAGTCATGTC-3'; *UPF1* forward, 5'-TCGAGGAAGTGAAGAAGACAC-3', and *UPF1* reverse, 5'-TCCGTTGCAGAACCCTC-3'.

For both experiments in SH-SY5Y cells, *UNC13A* CE was amplified with a forward primer in exon 20 (5'-CAAGCGAACTGACAAATCTGCCGTGTCG-3') and reverse primer within the CE (5'-CCTGGAAA GAACCTTATCCCAGGAAGTAGTTGTTG-3'); *UNC13B* FSE was amplified with a forward primer in exon 10 (5'-TCCGAGCAGTTACCAAGGTT-3') and reverse primer within the FSE (5'-GAAAAGCGAGGAGCCCTTCAG-3'); *STMN2* CE was amplified with a forward primer in exon 1 (5'-GCTCTCTCCGCTGCTGTAG-3') and reverse primer within the cryptic exon (5'-CTGTCTCTCTCTCGACA-3'); *HNRNP1* NMD transcript was amplified with a forward primer in the NMD-inducing exon (5'-GGTCGCAGTGTATGTTGATG-3') and reverse primer in exon 7 (5'-GGCGTTGTTGGGGTGTCT-3').

For *i*³Neuron experiments, iPS cells were infected sequentially, first with either control or a TDP-43 targeting sgRNA in the human pU6-sgRNA EF1A-Bsd-T2A-eGFP backbone, and then second with either a control or *UPF1*-targeting sgRNA in the bovine pU6-sgRNA EF1A-puro-T2A-BFP backbone for a total of 4 groups: control/control, control/*UPF1*, TDP43/control, TDP43/*UPF1*. Two days following each infection, iPS cells were selected with either blasticidin (first infection) or puromycin and blasticidin (second infection) (see 'CRISPRi knockdown in human iPS cells' for further details). iPS cells were then differentiated and neurons were collected in tri-reagent on day 7 after differentiation. Then RNA was isolated and cDNA was made (see 'RT-qPCR'). Then samples were analysed for differential gene expression and splicing by qPCR or PCR followed by Agilent bioanalyzer measurements to assess differences in band sizes resulting from cryptic exon splicing. PCR products were diluted 1:10 in nuclease-free water and resolved on a Bioanalyzer 2100 (Agilent). Bands were quantified with Agilent 2100 Software (Version B.02.08.SI648) using High sensitivity DNA Assay (Version 1.03). *UNC13A* primers are listed under RT-PCR.

Quantification of TDP-43, *UNC13A* and *UNC13B* using quantitative proteomics

*i*³Neurons were collected from 6-well plates on day 17 after the initiation of differentiation. One or two wells were pooled for each biological replicate, $n = 6$ for each control and TDP-43-knockdown neurons. To collect cells, wells were washed with PBS, and then SP3 protein extraction was performed to extract intracellular proteins. In brief, we collected and lysed using a very stringent buffer (50 mM HEPES, 50 mM NaCl, 5 mM EDTA 1% SDS, 1% Triton X-100, 1% NP-40, 1% Tween 20, 1% deoxycholate and 1% glycerol) supplemental with cComplete protease inhibitor cocktail at 1 tablet/10 ml ratio. The cell lysate was reduced by 10 mM dithiothreitol (30 min, 60 °C) and alkylated using 20 mM iodoacetamide (30 min, dark, room temperature). The denatured proteins were captured by hydrophilic magnetic beads, and tryptic on-beads digestion was conducted for 16 h at 37 °C. We injected 1 µg resulting peptides to a nano liquid chromatography for separation, and subsequently those tryptic peptides were analyzed on an Orbitrap Eclipse mass spectrometer coupled with a FAIMS interface using data-dependent acquisition (DDA) and data-independent acquisition (DIA) controlled by Xcalibur v4.3. The peptides were separated on a 120 min LC gradient with 2-35% solvent B (0.1% FA, 5% DMSO in acetonitrile), and FAIMS's compensation voltages were set to -50, -65 and -80. For DDA, we used MS1 resolution at 12,000 and cycle time was selected for 3 s, MS2 fragments were acquired by linear ion trap. For DIA, we used 8 m/z isolation windows (400-1,000 m/z range), cycle time was set to 3 s, and MS2 resolution was set to 30,000. The DDA and DIA MS raw files were searched against Uniprot-Human-Proteome_UP000005640 database with 1% FDR using Proteome Discoverer (v2.4) and Spectronaut (v14.1), respectively. The raw intensity of quantified peptides was normalized by total peptides intensity identified in the same sample. The DDA quantified TDP-43- and *UNC13A*-derived unique and sharing peptides were parsed out

and used for protein quantification. Specifically, we visualized and quantified the unique peptides of *UNC13A* using their MS/MS fragment ion intensity acquired by DIA.

Nanopore sequencing and analysis

RNA from four FTLD-TDP patient samples and four SHSY-5Y samples (two with doxycycline-induced TDP-43 knockdown and two untreated controls) was reverse transcribed using Superscript IV (Thermo Fisher Scientific) using a specific reverse transcription primer following the manufacturer recommendations, but with the volumes halved. Following heat inactivation of the reverse transcriptase, the samples were treated with RNase H (NEB) for 20 min at 37 °C, then diluted fourfold with Phusion HF mastermix (Thermo Fisher Scientific). Two rounds of nested PCR were performed to generate pure amplicons spanning the exon upstream of the CE and the exon downstream of the TDP-43 regulated intron retention, with thermolabile exol treatment in between (NEB). To ensure complete amplification of amplicons, a 10 min extension time was used (approximately 10× longer than recommended by the manufacturer's protocol). Nanopore-compatible overhangs were then added by PCR and the products were validated by agarose electrophoresis, followed by barcode addition using primers 5-12 from the Nanopore PCR barcoding kit (SQK-PBK004). Following ligase-free rapid adaptor addition (SQK-PBK004) the products were loaded onto and sequenced with a MinION. Demultiplexing and basecalling was performed in real time using the GUPPY basecaller.

Raw fastqs were aligned to a section of chromosome 19 containing the entire *UNC13A* gene (17690344-17599328; GRCh38.p13) using Minimap2⁴⁸ with settings "-ax splice". Downstream analysis was performed using a custom R script (https://github.com/frattalab/unc13a_cryptic_splicing) that quantified alignment to the regions of interest (the CE, the intron retention and their flanking exons), filtering for reads that were long enough to contain both the CE and intron retention so as not to bias the analysis against reads containing both events. Correct assignment was verified manually by visualizing differently classified reads.

Reverse transcription primer, CACATTGCCTGTGCCCTTAAC; nested PCR 1 forward, GACGTGTGGTACAACCTGGA; nested PCR 1 reverse, CACTCTTCAATGTGCGGCTG; nested PCR 2 forward, CTGACAAATCTGCCGTGTCG; nested PCR 2 reverse, GAAGCTGGTAGCAAACACCC; add overhang forward, TTTCTGTTGGTGTGATATTGC CTGACAAATCTGCCGTGTCG; add overhang reverse, ACTTGCCTGTGCTCTATCTTC GAAGCTGGTAGCAAACACCC.

Ribosome profiling

For ribosome-profiling experiments, *i*³Neurons were grown on 15 cm plates, one plate per biological replicate for control ($n = 4$) and TDP-43-knockdown ($n = 4$) neurons. On day 17, *i*³Neuron culture medium was replaced 90 min before collecting the neurons to boost translation. Then the medium was removed, cells were washed with cold PBS, PBS was removed and 900 µl of cold lysis buffer (20 mM Tris pH 7.4, 150 mM NaCl, 5 mM MgCl₂, 1 mM DTT (freshly made), 100 µg ml⁻¹ CHX, 1% TX100; 25 U ml⁻¹ Turbo DNase I) was added to each 15 cm plate. Lysed cells were scraped and pipetted into microcentrifuge tubes on ice. Cells were then passed through a 26-gauge needle 10 times, and then centrifuged twice at 19,000g at 4 °C, for 10 min, each time moving the supernatant to a fresh tube. Tubes containing supernatant were flash frozen in liquid nitrogen and stored at -80 °C until processing.

Ribosome footprints from three biological replicates of both TDP-43-knockdown control samples were generated and purified as described, using a sucrose cushion⁴⁹ and a customized library preparation method based on revised iCLIP⁵⁰. No ribosomal RNA depletion step was performed, and libraries were sequenced on an Illumina Hi-Seq 4000 machine (SR100). Reads were demultiplexed and adaptor/quality trimmed using Ultraplex⁵¹, then aligned with Bowtie2⁵² against a reference file containing abundant ncRNAs that are common contaminants

Article

of ribosome profiling, including rRNAs. Reads that did not pre-map were then aligned against the human genome with STAR³⁸ and the resulting BAM files were deduplicated with UMI-tools⁵³. Multi-mapping reads were discarded and reads 28–30 nt in length were selected for analysis. FeatureCounts⁴⁴ was used to count footprints aligning to annotated coding sequences, and DESeq2⁴¹ was used for differential expression analysis, using default parameters in both cases. Periodicity analysis was performed using a custom R script, using transcriptome-aligned bam files. Raw data have been uploaded to E-MTAB-10235.

ALS and FTD panel genes

To find ALS and FTD ‘green’ panel genes—those with diagnostic level of evidence that have been approached for testing by NHS in England—‘Amyotrophic lateral sclerosis/motor neuron disease (Version 1.33)’ and ‘Early onset dementia (encompassing fronto-temporal dementia and prion disease) (Version 1.48)’ were downloaded from PanelApp¹⁶.

Genome-wide association study data

Harmonized summary statistics for the latest ALS GWAS¹⁵ were downloaded from the NHGRI-EBI GWAS catalogue⁵⁴ (accession GCST005647). Locus plots were created using LocusZoom⁵⁵, using linkage disequilibrium values from the 1000 Genomes European superpopulation⁵⁶.

NYGC ALS Consortium RNA-seq cohort

Our analysis contains 377 patients with 1,349 neurological tissue samples from the NYGC ALS dataset, including non-neurological disease controls, FTLN, ALS, FTD with ALS (ALS-FTL), or ALS with suspected Alzheimer’s disease (ALS-AD). Patients with FTD were classified according to a pathologist’s diagnosis of FTD with TDP-43 inclusions (FTL-TDP), or those with FUS or Tau aggregates. ALS samples were divided into the following subcategories using the available Consortium metadata: ALS with or without reported SOD1 or FUS mutations. All non-SOD1 or FUS ALS samples were grouped as ALS-TDP in this work for simplicity, although reporting of postmortem TDP-43 inclusions was not systematic and therefore not integrated into the metadata. Confirmed TDP-43 pathology postmortem was reported for all FTL-TDP samples.

Sample processing, library preparation, and RNA-seq quality control have been extensively described in previous papers^{10,57}. In brief, RNA was extracted from flash-frozen postmortem tissue using TRIzol (Thermo Fisher Scientific) chloroform, and RNA-Seq libraries were prepared from 500 ng total RNA using the KAPA Stranded RNA-Seq Kit with RiboErase (KAPA Biosystems) for ribosomal RNA depletion. Pooled libraries (average insert size: 375 bp) passing the quality criteria were sequenced either on an Illumina HiSeq 2500 (125 bp paired end) or an Illumina NovaSeq (100 bp paired end). The samples had a median sequencing depth of 42 million read pairs, with a range between 16 and 167 million read pairs.

Samples were uniformly processed, including adapter trimming with Trimmomatic and alignment to the hg38 genome build using STAR (2.7.2a)³⁸ with indexes from GENCODE v30. Extensive quality control was performed using SAMtools⁵⁸ and Picard Tools⁵⁹ to confirm sex and tissue of origin.

Uniquely mapped reads within the *UNC13A* locus were extracted from each sample using SAMtools. Any read marked as a PCR duplicate by Picard Tools was discarded. Splice junction reads were then extracted with RegTools⁶⁰ using a minimum of 8 bp as an anchor on each side of the junction and a maximum intron size of 500 kb. Junctions from each sample were then clustered together using LeafCutter⁶¹ with relaxed junction filtering (minimum total reads per junction = 30, minimum fraction of total cluster reads = 0.0001). This produced a matrix of junction counts across all samples.

The CE was considered detected in a sample if there was at least one uniquely mapped spliced read supporting either the short CE acceptor or the CE donor. As the long CE acceptor was detected consistently in control cerebellum samples, as part of an unannotated cerebellum-enriched

35 bp exon containing a stop codon between exons 20 and 21 (Extended Data Fig. 10 a, b), we excluded the long CE acceptor for quantification of *UNC13A* CE ψ in patient tissue. Only samples with at least 30 spliced reads at the exon locus were included for correlations. In Fig. 4a, only cortical samples that were concordant for genotypes at *rs12973192* and *rs12608932*, had both *STMN2* and *UNC13A* CE detected, and had at least 30 spliced reads at the exon locus were included in the analysis. Cell-type deconvolution was performed using the top 100 most specific marker genes from neurons, astrocytes, oligodendrocytes, endothelial cells and microglia derived by single-cell RNA sequencing⁶² with the dtangle⁶³. The NYGC ALS Consortium samples presented in this work were acquired through various IRB protocols from member sites and the Target ALS postmortem tissue core and transferred to the NYGC in accordance with all applicable foreign, domestic, federal, state, and local laws and regulations for processing, sequencing, and analyses. The Biomedical Research Alliance of New York (BRANY) IRB serves as the central ethics oversight body for NYGC ALS Consortium. Ethical approval was given and is effective until 22 August 2022. Informed consent has been obtained from all participants.

Ethics

Brains were donated to the Queen Square Brain Bank (QSBB) for Neurological Disorders (QSBB) and the NeuroResource tissue bank (UCL Queen Square Institute of Neurology). All tissue samples were donated with the full informed consent. Accompanying clinical and demographic data of all cases used in this study were stored electronically in compliance with the 2018/1998 Data Protection Act and are summarized in Supplementary Table 5. Ethical approval for the study was obtained from the NHS research ethics committee (RNEC) and in accordance with the Human Tissue Authority’s codes of practice and standards under license number 12198. We have conformed with all relevant ethical regulations related to informed consent and anonymization of patient data analysed in the manuscript.

Gene transcript model harmonization

To ensure consistency between RNA-seq, re-analysis of published iCLIP data, and the NYGC ALS Consortium RNA-seq cohort, we confirmed that both the ENSEMBL gene minor version and transcripts for *UNC13A* and *UNC13B* are identical between the three GENCODE annotations used across our team.

BaseScope assay

To validate a BaseScope assay for *UNC13A* cryptic exons, we first performed the assay in i³Neurons with CRISPRi depletion of control or a non-targeting guide. Neurons were plated on 8-well IBIDI slides, 0.2 million per well and then fixed with 4% paraformaldehyde for 10 min on day 7 after the initiation of differentiation. Neurons were then dehydrated and stored for -1 week at -20°C. Neurons were then rehydrated and pretreated following the recommendations of the RNAscope® Assay for Adherent Cells, using 30% hydrogen peroxide for 8 min and a 1:15 dilution of the RNAscope Protease III. Then the BaseScope v2-RED assay was performed using our *UNC13A* CE target probe (BA-Hs-UNC13A-O1-Izz-st) according to manufacturer guidelines (Advanced Cell Diagnostics). Following fast red solution, wells were washed 2× with PBS, and incubated overnight at 4 °C in 0.5% Triton-X and 3% BSA containing primary antibodies: rabbit TDP43 (proteintech 12892-1-AP, 1:1,000 dilution) and mouse TUBB3 (Biolegend 801201, 1:5,000 dilution). The next morning, wells were washed three times with PBS and treated with secondary antibodies Alexa Fluor 488 anti-rabbit (Jackson Immuno 711-545-152) and Alexa Fluor 647 anti-mouse (Jackson Immuno 715-605-151), and Hoechst 33342 (Thermo Scientific) at 1:10,000 dilution for 1 h at room temperature. Wells were then washed 3× with PBS and imaged on an inverted spinning disk confocal microscope (Nikon Eclipse T1), using a 60× 1.40 NA oil-immersion objective. Confocal images were then processed in Fiji.

Article

intronic SNPs were extracted using a sliding-window approach. Using a custom R script (https://github.com/frattalab/unc13a_cryptic_splicing/), the average *E*-scores for each RBP were calculated for each set of 7-mers, and the RBPs were ranked by effect size of the SNPs on average *E*-score.

TDP-43 protein purification

His-tagged human TDP-43 (amino acids 102 to 269) was expressed in BL21-DE3 Gold *Escherichia coli* (Agilent) as previously described⁶⁷. Bacteria were lysed by 2 h of gentle shaking in lysis buffer (50 mM sodium phosphate pH 8, 300 mM NaCl, 30 mM imidazole, 1 M urea, 1% v/v Triton X-100, 5 mM β -mercaptoethanol, with Roche EDTA-free cComplete protease inhibitor) at room temperature. Samples were centrifuged at 16,000 rpm in a Beckman 25.50 rotor at 4 °C for 10 min, and the supernatant was clarified by vacuum filtration (0.22 μ m).

The clarified lysate was loaded onto a 5 ml His-Trap HP column (Cytiva) equilibrated with buffer A (50 mM sodium phosphate pH 8, 300 mM NaCl, 20 mM imidazole) using an AKTA Pure system, and eluted with a linear gradient of 0–100% buffer B (50 mM sodium phosphate pH 8, 300 mM NaCl, 500 mM imidazole) over 90 column volumes. The relevant fractions were then analysed by SDS–PAGE and then either extensively dialysed (3.5 kDa cutoff) against isothermal titration calorimetry (ITC) buffer (50 mM sodium phosphate pH 7.4, 100 mM NaCl, 1 mM TCEP) at 4 °C, or flash frozen in liquid nitrogen.

Isothermal titration calorimetry

RNAs with sequences 5'-AAGGAUGGAUGGAG-3' (CE SNP healthy), 5'-AAGCAUGGAUGGAG-3' (CESNP risk), 5'-AAAAAUGGAUGGUUGGAU-3' (intron SNP healthy) and 5'-AAAAAUGGAUGGGUGGAU-3' (intron SNP risk) were synthesized by Merck, resuspended in Ultrapure water, then dialysed against the same stock of ITC buffer used for TDP-43 dialysis (above) overnight at 4 °C using 1 kDa Pur-a-lyzer tubes (Merck). Protein and RNA concentrations after dialysis were calculated by A280 and A260 absorbance respectively. ITC measurements were performed on a MicroCal PEAQ-ITC calorimeter (Malvern Panalytical). Titrations were performed at 25 °C with TDP-43 (9.6–12 μ M) in the cell and RNA (96–120 μ M) in the syringe. Data were analysed using the MicroCal PEAQ-ITC analysis software using nonlinear regression with the One set of sites model. For each experiment, the heat associated with ligand dilution was measured and subtracted from the raw data.

iCLIP of SH-SH5Y and minigene-transfected HEK 293T cells

SH-SY5Y cells were grown to 80% confluence in two 10 cm dishes. HEK 293T cells were grown to 80% confluence and transfected with either the 2 \times healthy or 2 \times risk minigenes using Lipofectamine 3000 (ThermoFisher Scientific). Each replicate consisted of 2 \times 3.5 cm dishes, with two replicates per sample, for eight dishes total. Plasmid (1.25 μ g) was used for each dish, measured via Nanodrop (Thermo Fisher Scientific), combined with 2.5 μ l of Lipofectamine 3000 and P3000 reagent diluted in 250 μ l (2 \times 125 μ l) of Opti-MEM I following the manufacturer protocol (Thermo Fisher Scientific). Cells were UV crosslinked on ice and subjected to iCLIP analysis following the iiCLIP protocol⁵⁰. In brief, medium RNase I was added to cell lysate for RNA fragmentation. Immunoprecipitations were performed with 4 μ g of TDP-43 antibody ((Proteintech, Rabbit anti-TDP-43 cat. no. 10782-2-AP) coupled with 100 μ l of protein A or G dynabeads (for SH-SY5Y or HEK 293T, respectively) per sample. The complexes were then size-separated with SDS–PAGE and visualized by Odyssey scanning. cDNA was synthesized with Superscript IV Reverse Transcriptase (Life Technologies). cDNA was then circularized. After PCR amplification, libraries were removed from primers with Ampure beads and QCed for sequencing. Libraries were sequenced on an Illumina HiSeq4000 machine (SR100).

For SH-SH5Y iCLIP, downstream analysis was performed with the iMAPS server. For data from HEK 293T cells, after demultiplexing the reads with Ultrplex, we initially aligned to the human genome using STAR³⁸, which showed that >5% of uniquely aligned reads mapped solely

to the genomic region that is contained in the minigene. Given the high prior probability of reads mapping to the minigene, we therefore instead used Bowtie2 to align to the respective minigene sequences alone, thus minimizing mis-mapping biases that could be caused by the SNPs⁵² with settings "--norc --no-unal --rdg 50,50 --rfg 50,50 --score-min L,-2,-0.2 --end-to-end -N1", then filtered for reads with no alignment gaps, and length >25 nt. Due to the exceptional read depth and high library complexity, we did not perform PCR deduplication to avoid UMI saturation at signal peaks. All downstream analysis was performed using custom R scripts; to avoid biases due to differing transfection efficiencies, crosslink densities were normalized by the total number of minigene crosslinks for each sample. Raw data are available at E-MTAB-10297.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

Data availability

A minimum dataset to reproduce analyses is freely available at https://github.com/frattalab/unc13a_cryptic_splicing/tree/main/ data. RNA-seq data for i3Neurons, SH-SY5Y and SK-N-DZ^a are available through the European Nucleotide Archive (ENA) under accession PRJEB42763. NYGC ALS Consortium RNA-seq: RNA-seq data generated through the NYGC ALS Consortium in this study can be accessed via the NCBI GEO database (GSE137810, GSE124439, GSE116622 and GSE153960). To request immediate access to new data generated by the NYGC ALS Consortium and for samples provided through the Target ALS Postmortem Core, complete a genetic data request form at CGND_help@nygenome.org. NYGC ALS Consortium genotypes for the common SNPs in this study *rs129731921* and *rs12608932* are available at https://github.com/frattalab/unc13a_cryptic_splicing/blob/main/data/nygc_junction_information.csv. Source data are provided with this paper.

Code availability

Analysis code and data to reproduce figures are freely available at https://github.com/frattalab/unc13a_cryptic_splicing/. The tool for demultiplexing iCLIP reads is freely available at <https://github.com/ulelab/ultraplex>. Snakemake pipelines to perform RNA-seq alignment, splicing and parsing splice junction files are freely available at https://github.com/frattalab/rna_seq_snakemake/, <https://github.com/frattalab/splicing/> and https://github.com/frattalab/bedops_parse_star_junctions/. The Snakemake pipeline for analysing publicly available iCLIP is available at https://github.com/frattalab/pipeline_iclip.

34. Thorvaldsdóttir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief. Bioinform.* **14**, 178–192 (2013).
35. Rodriguez, J. M. et al. APPRIS 2017: principal isoforms for multiple gene sets. *Nucleic Acids Res.* **46**, D213–D217 (2018).
36. Middleton, R. et al. IRFinder: assessing the impact of intron retention on mammalian gene expression. *Genome Biol.* **18**, 51 (2017).
37. Gilbert, L. A. et al. Genome-scale CRISPR-mediated control of gene repression and activation. *Cell* **159**, 647–661 (2014).
38. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
39. Frankish, A. et al. GENCODE reference annotation for the human and mouse genomes. *Nucleic Acids Res.* **47**, D766–D773 (2019).
40. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* **30**, 923–930 (2014).
41. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
42. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat. Methods* **14**, 417–419 (2017).
43. Mølder, F. et al. Sustainable data analysis with Snakemake. *FI000Research* **10**, 33 (2021).
44. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841–842 (2010).
45. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2^{- $\Delta\Delta$ CT} method. *Methods* **25**, 402–408 (2001).

46. Pereverzev, A. P. et al. Method for quantitative analysis of nonsense-mediated mRNA decay at the single cell level. *Sci. Rep.* **5**, 7729 (2015).
47. Humphrey, J. et al. FUS ALS-causative mutations impair FUS autoregulation and splicing factor networks through intron retention. *Nucleic Acids Res.* **48**, 6889–6905 (2020).
48. Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* **34**, 3094–3100 (2018).
49. McGlincy, N. J. & Ingolia, N. T. Transcriptome-wide measurement of translation by ribosome profiling. *Methods* **126**, 112–129 (2017).
50. Lee, F. C. Y. et al. An improved iCLIP protocol. Preprint at <https://doi.org/10.1101/2021.08.27.457890> (2021).
51. Wilkins, O. G., Capitanichik, C., Luscombe, N. M. & Ule, J. Ultraplex: A rapid, flexible, all-in-one fastq demultiplexer. *Wellcome Open Res.* **6**, 141 (2021).
52. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9**, 357–359 (2012).
53. Smith, T., Heger, A. & Sudbery, I. UMI-tools: modeling sequencing errors in Unique Molecular Identifiers to improve quantification accuracy. *Genome Res.* **27**, 491–499 (2017).
54. Buniello, A. et al. The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* **47**, D1005–D1012 (2019).
55. Pruim, R. J. et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* **26**, 2336–2337 (2010).
56. 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature* **526**, 68–74 (2015).
57. Tam, O. H. et al. Postmortem cortex samples identify distinct molecular subtypes of ALS: retrotransposon activation, oxidative stress, and activated glia. *Cell Rep.* **29**, 1164–1177.e5 (2019).
58. Li, H. et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).
59. Picard toolkit. Broad Institute, GitHub Repository <https://broadinstitute.github.io/picard/> (Broad Institute, 2019).
60. Cotto, K. C. et al. RegTools: Integrated analysis of genomic and transcriptomic data for the discovery of splicing variants in cancer. Preprint at <https://doi.org/10.1101/436634> (2021).
61. Li, Y. I. et al. Annotation-free quantification of RNA splicing using LeafCutter. *Nat. Genet.* **50**, 151–158 (2018).
62. Darmanis, S. et al. A survey of human brain transcriptome diversity at the single cell level. *Proc. Natl Acad. Sci. USA* **112**, 7285–7290 (2015).
63. Hunt, G. J., Freytag, S., Bahlo, M. & Gagnon-Bartsch, J. A. dtangle: accurate and robust cell type deconvolution. *Bioinformatics* **35**, 2093–2099 (2019).
64. Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at <https://arxiv.org/abs/1303.3997> (2013).
65. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat. Genet.* **43**, 491–498 (2011).
66. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* **20**, 1297–1303 (2010).
67. Lukavsky, P. J. et al. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. *Nat. Struct. Mol. Biol.* **20**, 1443–1449 (2013).

Acknowledgements We thank F. Allain for the His-tagged TDP-43 plasmid; C. Stuani, F. Weissmann, M. Watson and K. Stott for guidance on TDP-43 purification and ITC; A. Isaacs and P. Whiting for support with shRNA experiments; N. Seyfried for input on proteomic

experiments; and J. Vargas for his scientific insights and engaging conversations. This work was supported by grants from UK Medical Research Council MR/R005184/1 (E.M.C.F. and P.F.), FC001002 (J.U.); NIH U54NS123743 (P.F.); UK Motor Neurone Disease Association (P.F.); Rosetrees Trust (P.F. and A.G.); Chan Zuckerberg Initiative (M.E.W.); The Robert Packard Center for ALS Research (M.E.W., P.F. and E.M.C.F.); AriSLA (E.B.); Alzheimers Society (A.G.); NIH T32 GM136577 (S.S.); NIH National Institute of Aging R56-AG055824 and U01-AG068880 (J.H. and T.R.); European Union's Horizon 2020 research and innovation programme 835300 (J.U.); Cancer Research UK FC001002 (J.U.); Wellcome Trust FC001002 (J.U.); Collaborative Center for X-linked Dystonia-Parkinsonism (W.C.L. and E.M.C.F.). P.F. is supported by a UK Medical Research Council Senior Clinical Fellowship and Lady Edith Wolfson Fellowship (MR/M008606/1 and MR/S006508/1), the UCLH NIHR Biomedical Research Centre; M.E.W. and S.E.H. are supported by the NIH Intramural Research Program of the National Institutes of Neurological Disorders and Stroke; O.G.W. is supported by a Wellcome Trust Studentship; M.Z. is supported by the Neurological Research Trust; S.C. is supported by NIH Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development; A.B. is supported by Eisai and the Wolfson Foundation; S.E.H. is supported by a Brightfocus Foundation postdoctoral research fellowship; T.L. is supported by an Alzheimer's Research UK senior fellowship; G.S. is supported by a Wellcome Trust Investigator Award (107116/Z/15/Z) and UK Dementia Research Institute Foundation award (UKDRI-1005); M.S. is supported by a UKRI Future Leaders Fellowship (MR/TO42184/1); S.B.-S. is supported by a UK Motor Neurone Disease Association and Masonic Charitable Foundation PhD Studentship (893-792); M.H. is supported by a Lady Edith Wolfson Senior Non-Clinical Fellowship (959-799); S.S. is supported by the NIH Oxford–Cambridge Scholars Program.

Author contributions Conceptualization: A.-L.B., O.G.W., M.J.K., S.E.H., J.H., M.E.W. and P.F. Data curation: A.-L.B., O.G.W., M.Z., W.C.L. and S.B.-S. Formal analysis: A.-L.B., O.G.W., M.J.K., M.Z., W.C.L., S.B.-S., A.B., M.H., E.K.G., S.S., J.F.R., S.L.C. and D.R. Funding acquisition: P.F., M.E.W. and E.B. Investigation: A.-L.B., O.G.W., M.J.K., S.E.H., M.Z., W.C.L., F.C.Y.L., L.M., Y.A.Q., S.B.-S., A.B., A.G., M.H., E.K.G., S.S., J.F.R., S.L.C., D.R., E.K.G. and S.L.C. Methodology: A.-L.B., O.G.W., M.J.K., S.E.H., J.H., M.E.W. and P.F. Project administration: P.F. and M.E.W. Resources: H.P., T.L., E.B., D.F. and J.N. Software: A.-L.B., O.G.W., M.Z., S.B.-S., J.H. and M.J.K. Supervision: P.F., M.E.W., J.H., J.U., M.S., T.R., T.L., E.M.C.F., G.S. and T.F. Visualization: A.-L.B., O.G.W., M.J.K., W.C.L. and S.E.H. Writing, original draft: A.-L.B., O.G.W., M.J.K., M.E.W. and P.F. Writing, review and editing: S.E.H., W.C.L., E.B., J.U., J.H., M.E.W., P.F. A.-L.B., O.G.W., M.J.K. and S.E.H. contributed equally; therefore each may place their name first in author order when referencing this manuscript in personal communications.

Competing interests A patent application related to this work has been filed. The technology described in this work has been protected in the patent PCT/EP2021/084908 and UK patent 2117758.9 (patent applicant, UCL Business Ltd and NIH; status pending), in which A.-L.B., O.G.W., M.J.K., S.E.H., M.E.W. and P.F. are named as inventors. The other authors declare no competing interests.


Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41586-022-04436-3>.

Correspondence and requests for materials should be addressed to Andrea Malaspina or Pietro Fratta.

Peer review information *Nature* thanks Noa Lipstein, Magdalini Polymenidou and the other, anonymous, reviewers for their contribution to the peer review of this work. Peer review reports are available.


Reprints and permissions information is available at <http://www.nature.com/reprints>.



Extended Data Fig. 1 | See next page for caption.


Extended Data Fig. 1 | *UNC13A* and *UNC13B* are misspliced after TDP-43 knockdown across neuronal lines. (a, b) RNA-seq traces from IGV³⁴ of representative samples from control (top) and *TARDBP*KD (bottom) in i³Neurons showing intron retention in *UNC13A* (A) (mean 4.50 ± 1.50 increased IR in KD) and *UNC13B* (mean 1.86 ± 0.63 increased IR in KD)(B), overlaid with published TDP-43 iCLIP peaks²² (c) Histogram showing number of basescope cryptic foci per nuclei in control (blue) and TDP-43 KD (grey) in WTC11-derived i³Neurons, $p < 0.0001$ unpaired t-test. (d, e) RT-qPCR levels of *TARDBP* and *UNC13A* with a non-targeting control sgRNA (sgTARDBP⁻), an intermediate TDP-43 KD (sgTARDBP⁺) or a higher TDP-43 KD (sgTARDBP⁺⁺) in WTC11-derived (d) and NCRM-5-derived i³Neurons (e). $n = 4$ biological replicates sgTARDBP⁻ (d), $n = 6$ biological replicates sgTARDBP⁻ (e), sgTARDBP⁺ (d, e) and ++ (d, e), plotted as means \pm SEM. (f) Representative images of *UNC13A* CE RT-PCR products (g) Quantification of the lower gel in (f) plotted as

means \pm SEM, $n = 6$ biological replicates non-targeting control sgRNA (sgTARDBP⁻), sgTARDBP⁺, sgTARDBP⁺⁺. Upper gel is quantified in Fig. 1h. One-way ANOVA with multiple comparisons. (h-k) Expression of TDP-43 regulated splicing in *UNC13A* (h, i) and *UNC13B* (j, k) across neuronal datasets^{9,21} in control (blue) and TDP-43 KD (yellow). Intron retention (IR) (i, k) and CE and fsE PSI (h, j) significantly increase after TDP-43 depletion in most experiments, Wilcoxon test (l) Relative gene expression levels for *TARDBP* across neuronal datasets^{9,21}. Normalized RNA counts are shown as relative to control mean. Numbers show log₂ fold change calculated by DESeq2. Significance shown as adjusted p-values from DESeq2. For (h-l) biological replicates are: iPSC MN Ctrl KD $n = 12$, TDP-43 KD $n = 6$; i³N Ctrl KD $n = 4$, TDP-43 KD $n = 3$; SH-SY5Y, SK-N-DZ^a, and SK-N-DZ^b Ctrl KD $n = 3$, TDP-43 KD $n = 3$, Significance levels reported as * ($p < 0.05$) ** ($p < 0.01$) *** ($p < 0.001$) **** ($p < 0.0001$).



Extended Data Fig. 2 | Validation of *UNC13A* and *UNC13B* missplicing after TDP-43 KD across multiple neuronal cell lines. Targeted nanopore sequencing reveals *UNC13A* CE and IR events occur largely independently in-vitro. (a) Sanger sequencing of cryptic bands in both SH-SY5Y and SK-N-DZ cells confirm the CE splice junctions. (b, c) Crosslink density across *UNC13A* (chr19) (b) and *UNC13B* (chr9) (c) genomic loci from novel iCLIP on endogenous TDP-43 in SH-SY5Y cells. Crosslink densities for both genes show peaks at the

CE/fsE (red) and retained introns (blue). Coordinates shown in hg38. (d) Percentage of all targeted *UNC13A* long reads in SH-SY5Y cells containing either neither CE nor IR, both, or either CE or IR. Most reads in both control and TDP-43 KD contain neither event, and while IR event is present in controls, CE is only detected in TDP-43 KD. (e) Representative trace in TDP-43 KD of *UNC13A* targeted long reads showing transcript containing either the CE or IR, and transcripts with neither.




Extended Data Fig. 3 | See next page for caption.

Article


Extended Data Fig. 3 | Reduction of *UNC13A* and *UNC13B* after TDP-43 knockdown correlates with TDP-43 levels and is caused by nonsense-mediated decay. Relative gene expression levels for *UNC13A* (a) and *UNC13B* (b) after TDP-43 knockdown across neuronal cell lines^{9,21}. Normalized RNA counts are shown as relative to control mean. Numbers show log fold change calculated by DESeq2. Significance shown as adjusted p-values from DESeq2. Number of replicates as in Extended data Fig. 1 H-L (c, d) RT-qPCR analysis shows *TDP-43*, *UNC13A* and *UNC13B* gene expression is reduced by *TARDBP* shRNA knockdown in both SH-SY5Y and SK-N-DZ human cell lines. Graphs represent the means \pm SEM, n = 6 biological replicates, one sample t-test. (e) The 5' ends of 29 nt reads relative to the annotated start codon from a representative ribosome profiling dataset (TDP-43 KD replicate B). As expected, we detected strong three-nucleotide periodicity, and a strong enrichment of reads across the annotated coding sequence relative to the upstream untranslated region. (f) *UNC13A*, *UNC13B*, and TDP-43 protein levels, measured by Western Blot, with varying levels of DOX-inducible TDP-43

knockdown in SH-SY5Y cells. Tubulin is used as endogenous control, n = 3. For gel source data, see Supplementary Figure 1. (g) Quantification of RT-PCR products from the transcripts containing *UNC13A* CE, *UNC13A* intron retention, *UNC13B* fsE, and *UNC13B* intron retention, with varying levels of DOX-inducible TDP-43 knockdown in SH-SY5Y cells. Graphs represent the means \pm SEM n = 3 biological replicates. (h) UPF1 siRNA knock-down led to the rescue of *hnRNPL* (positive control), *UNC13A*, and *UNC13B* transcripts, but not *STMN2*. Graphs represent the means \pm SEM, n = 4 biological replicates, one-sample t-test. (i) *UNC13A* CE containing-transcript PSI is increased after UPF1 knockdown in i³Neurons. Graphs represent the means \pm SEM, n = 6 biological replicates. (j) RT-PCR products from *UNC13A* in the setting of mild TDP-43 knockdown (“+”, as for Figure 2C and S4G) with the addition of either DMSO (control) or CHX (NMD inhibition). (k) Quantification of (j) Graphs represent the means \pm SEM, n = 4 biological replicates. Significance levels reported as * (p < 0.05) ** (p < 0.01) *** (p < 0.001) **** (p < 0.0001).




Extended Data Fig. 4 | Sample technical factors in NYGC tissue samples do not vary in a systematic way. (a) *UNC13A* expression across tissues and disease subtypes in the NYGC ALS Consortium RNA-seq dataset. Expression normalised as transcripts per million (TPM). Cortical regions have noticeably higher *UNC13A* expression than the spinal cord. (b) total RNA-seq library size (log₁₀ scaled) (c) RNA integrity score (RIN) (d) Cell type decomposition across

NYGC ALS Consortium RNA-seq dataset. While there are differences between tissues and disease-subtypes on these technical factors, specificity of *UNC13A* CE detection to tissues presumed to contain TDP-43 proteinopathy cannot be explained by these technical factors. Box plots (a–d): boundaries 25–75th percentiles; midline, median; whiskers, Tukey style. Wilcoxon test, significance levels reported as * ($p < 0.05$) ** ($p < 0.01$) *** ($p < 0.001$) **** ($p < 0.0001$).




Extended Data Fig. 5 | Differences in sample technical factors where *UNC13A* CE was detected and undetected vary between cortical and spinal tissues. Targeted long reads in FTLN frontal cortex show that *UNC13A* CE and IR occur independently in-vivo. (a) Detection rate of *UNC13A* CE across tissues by RNA sequencing platform and read length. *UNC13A* CE was more likely to be detected in cervical spinal cord and motor cortex when sequenced on machines with 125 bp compared to 100 bp. (b) No significant differences in total RNA-seq library size (log10 scaled). (c) RNA integrity score (RIN) was significantly lower in motor and temporal cortices in samples where *UNC13A* was detected. (d) Cell type decomposition revealed that samples with *UNC13A* CE detected had a higher proportion of neurons in cervical and lumbar spinal

cord, whereas in frontal, temporal, and motor cortex samples with *UNC13A* CE detected had a lower proportion of neurons, and in motor and temporal cortex samples with *UNC13A* CE detected had a higher proportion of astrocytes. Astrocy. - Astrocytes, Endoth. - Endothelial, Microgl. - Microglia, Neur. - Neurons, Oligodendr. - Oligodendrocytes. P-values shown are from Fisher's exact test (a) or Wilcoxon test (b-d). N tissue samples show below in brackets. Box plots (a-d): boundaries 25-75th percentiles; midline, median; whiskers, Tukey style. (e) Percentage of targeted *UNC13A* long reads with TDP-43 regulated splice events that contain either both, CE, or IR in four in FTLN frontal cortices. (f) Percentage of all targeted *UNC13A* long reads in (a) containing neither CE nor IR, both, or either CE or IR.




Extended Data Fig. 6 | Expression of shorter *UNC13B* isoform in human neuronal tissue masks detection of *UNC13B* fsE across NYGC tissue samples. (a) Expression of splice junction reads supporting the *UNC13B* fsE across tissues and disease subtypes. Junction counts are normalised by library size in millions (junctions per million). Expression of *UNC13B* fsE is present across controls and ALS/FTLD-non-TDP tissues. Wilcoxon test, significance levels reported as * ($p < 0.05$) ** ($p < 0.01$) *** ($p < 0.001$) **** ($p < 0.0001$). (b) Diagram showing three of the *UNC13B* transcripts, including the APPRIS³⁵

principal isoform *UNC13B-207* (blue), the NMD sensitive isoform *UNC13B-208* (green), and the shorter isoform *UNC13B-210* which shares the fsE (light green highlight) and one of the splicing junctions supporting the fsE as *UNC13B-208*. (c) Expression of three *UNC13B* isoforms across NYGC cohort and in the five in vitro TDP-43 knockdowns experiments⁹²¹. *UNC13B-210* is expressed across in vivo human tissues, whereas there is almost no expression of *UNC13B-210* in any of the in vitro experiments. Box plots (a, c): boundaries 25–75th percentiles; midline, median; whiskers, Tukey style.



Extended Data Fig. 7 | TDP-43 regulated *UNC13A* and *UNC13B* introns are expressed across human neuronal tissues in NYGC tissue samples. *STMN2* CE PSI correlates with TDP-43 regulated cryptics across NYGC RNA-seq dataset. IRratio³⁶ in *UNC13A* exon 31–32 (a) and *UNC13B* exon 21–22 (b) across NYGC tissue samples. *UNC13A* IR was lower in ALS-TDP cases than in controls in cervical spinal, frontal and motor cortices, and higher in FTLD-TDP cases than controls in frontal and temporal cortices. Possibly this reflects differences in

the effects of cell type composition in disease state. Box plots (a, b): boundaries 25–75th percentiles; midline, median; whiskers, Tukey style.. Wilcoxon test, significance levels reported as * ($p < 0.05$) ** ($p < 0.01$) *** ($p < 0.001$) **** ($p < 0.0001$). (c–e) Correlation in ALS/FTLD-TDP cortex between *RAP1GAP* CE (c), *PFKP* CE (d), and *UNC13A* CE (e) with *STMN2* CE PSI in patients with at least 30 spliced reads across the CE locus. Spearman's correlation.




Extended Data Fig. 8 | See next page for caption.

Article

Extended Data Fig. 8 | *UNC13A* risk alleles increase *UNC13A* CE expression after TDP-43 depletion by altering TDP-43 binding affinity across the *UNC13A* CE-containing intron. (a) *UNC13A* CE PSI by genotype (Wilcoxon test) Box plots: boundaries 25-75th percentiles; midline, median; whiskers, Tukey style. (b) Effect of CE or intronic SNP on the correlation between STMN2 and *UNC13A* CE PSI in ALS/FTD cortex in samples with at least 30 junction reads across the CE locus. Spearman's correlation. (c) Raw tapestation gel images of *UNC13A* CE products in 2H and 2R minigenes and quantification of the PCR products. Graphs represent the means \pm SEM (n = 3 biological replicates); Two-way ANOVA (d) Raw tapestation gel images corresponding to Fig. 4e. Two sets of primers were used to amplify either control (top row) or mutant minigene (bottom row). Left panel: single transfections were performed to


ensure primer specificity. Right panel: three biological replicates of the double transfections. (e) Fractional changes at iCLIP peaks for 2R versus 2H minigene (mean and 75% confidence interval shown). Peaks that are within 50nt of each SNP are highlighted. (f) Mean crosslink density around the exonic (top) and intronic (bottom) SNPs in the 2H (red) and 2R (blue) minigenes, relative to the 5' end of minigene (error bars = standard deviation; dashed lines show SNP positions). (g, h) Individual TDP-43 E-scores for the CE (g) and intronic (h) heptamers for which there was data²⁷ (i) Average change in E-value (measure of binding enrichment) across proteins for heptamers containing risk/healthy intronic SNP allele; TDP-43 is indicated in red. Significance levels reported as * (p < 0.05) ** (p < 0.01) *** (p < 0.001) **** (p < 0.0001).



Extended Data Fig. 9 | Binding of TDP-43 to SNP-containing intronic RNA. (a–d) ITC measurement of the interaction of TDP-43 with 14-nt RNA containing the CE SNP (a, b) and intronic SNP (c, d) healthy sequence. A representative data set is reported, with raw data (a, c) and integrated heat plot (b, d). Circles indicate the integrated heat; the curve represents the best fit. (e) Raw Tapestation gel images corresponding to Fig. 4j. For each experiment, two

RT-PCRs were performed with a different primer set which either amplified a control minigene (top row; minigene 2H) or a mutant minigene (bottom row). Left: single transfections to ensure specificity of primers for either the control or the mutant minigene. Right: Three replicates of double transfections with control minigene 2H and either mutant minigene.

Article



Extended Data Fig. 10 | One of the splice junctions for *UNC13A* CE overlaps with an unannotated exon expressed in control cerebellum. (a) Expression of splice junction reads supporting the *UNC13A* CE across tissues and disease subtypes. Junction counts are normalised by library size in millions (junctions per million). The long novel acceptor junction is expressed across all disease

subtypes in the cerebellum. Box plots: boundaries 25–75th percentiles; midline, median; whiskers, Tukey style. **(b)** Example RNA-seq traces from IGV showing *UNC13A* cerebellar exon which shares the long novel acceptor junction as the *UNC13A* CE.

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

Proteome Discoverer (v2.4)
 featureCounts v1.6.4
 ultraplex v1.1.2
 Bowtie2 v2.4.2
 UMI-tools v1.0.1
 LocusZoom
 regtools v0.5.1
 samtools v1.9
 Picard Tools v2.4.1
 ImageJ v1.52p

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Minimum data to reproduce results freely available: https://github.com/frattalab/unc13a_cryptic_splicing/tree/main/data

RNA-Seq Data for i3Neurons, SH-SY5Y and SK-N-DZa are available through the European Nucleotide Archive (ENA) under accession PRJEB42763 (Fig 1,2, fig S1).

Public data was obtained from Gene Expression Omnibus (GEO): iPSC MNs (Klim et al., 2019)-GSE121569, SK-N-DZb-GSE97262, and FACS-sorted frontal cortex neuronal nuclei-GSE126543 (Fig 1,2,3, fig S1).

Riboseq: E-MTAB-10235 (Fig 2, fig S2).

Targeted RNA seq: E-MTAB-10237 (Fig 4)

Minigene iCLIP: E-MTAB-10297 (Fig 4)

NYGC ALS Consortium RNA-seq: RNA-Seq data generated through the NYGC ALS Consortium in this study can be accessed via the NCBI's GEO database (GEO GSE137810, GSE124439, GSE116622, and GSE153960). All RNA-Seq data generated by the NYGC ALS Consortium are made immediately available to all members of the Consortium and with other consortia with whom we have a reciprocal sharing arrangement. To request immediate access to new and ongoing data generated by the NYGC ALS Consortium and for samples provided through the Target ALS Postmortem Core, complete a genetic data request form at ALSData@nygenome.org. (Fig 3,4, fig S5,6,S8-11,S13)

NYGC ALS Consortium Whole Genome Seq: to be released later with companion manuscript.

NYGC ALS Consortium genotypes on common SNPs in this study rs129731921 and rs12608932 are present at https://github.com/frattalab/unc13a_cryptic_splicing/blob/main/data/nygc_junction_information.csv

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample size in NYGC ALS Consortium was not determined in advance, the consortium data collection is ongoing, and sample size was determined by the number of available RNA-seq and genomically matched samples available at start time of analysis (2020-07). Sample size for RNA-seq on cell lines new to this study was determined by prior literature using similar experimental approaches rather than by power analysis. Examples of similar RNA-seq studies using similar (n of at least 3 in each condition) samples size include "Major hnRNP proteins act as general TDP-43 functional modifiers both in Drosophila and human neuronal cells" and "Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration"
Data exclusions	Tissue samples with discordant genotype on rs12608932 and rs12973192 (2) were excluded from the analysis on genotype effect on the ratio of UNC13A/STMN2 cryptic PSI.
Replication	Expression of the UNC13A CE was replicated in multiple independent cell lines, WTC11 iPSC and NCRM5 iPSC cell lines. Minigene experiments were replicated in 3 biological replicates. SH-SY5Y doxycycline knock-downs were replicated in 3 biological replicates.
Randomization	Not relevant to this study as no randomization is required due to the homogeneous nature of the cell lines. Furthermore, our RNA-seq discovery assays are high-throughput and were initially done in a hypotheses-free analysis. Observations in the RNA-seq were validated and confirmed by biochemical assays to bolster initial observations from the high-throughput assays.
Blinding	BaseScope cortical sections were imaged and analysed blinded to disease status.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Included in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Included in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used

Rabbit anti-UNC13A (Synaptic Systems 126 103) dilution 1:2,000
 Rabbit anti-UNC13B (abcam ab97924) dilution 1:1,000
 Rat anti-Tubulin (abcam ab6161 clone YOL1/34) dilution 1:5,000
 Mouse anti-TDP-43 (abcam ab104223 clone 3H8) dilution 1:5,000
 Rabbit anti-TDP-43 10782-2-AP (Proteintech) - lot 00065465
 Goat anti-Rabbit HRP (Bio-Rad 1706515) 1:10,000
 Goat anti-Mouse HRP (Bio-Rad 1706516) 1:10,000
 Rabbit anti-Rat HRP (Dako P0450) 1:10,000
 Donkey anti-Rabbit 488 (Jackson Immuno 711-545-152)
 Donkey anti-Mouse 647 (Jackson Immuno 715-605-151)
 Rabbit anti-TDP-43 (Proteintech 12892-1-AP)
 Mouse anti-TUBB3 (Biolegend 801201)

Validation

Mouse anti-TDP43 abcam ab104223 was validated via shRNA experiments against TDP-43

Rb anti-UNC13A (synaptic systems 126 103) has been previously verified in KO mouse [Lai Y, Choi UB, Leitz J, Rhee HJ, Lee C, Altas B, Zhao M, Pfuetzner RA, Wang AL, Brose N, Rhee J, et al. Molecular Mechanisms of Synaptic Vesicle Priming by Munc13 and Munc18. Neuron (2017) 953: 591-607.e10.]. The antibody was additionally validated by western blot analysis of human brain lysate and U2OS cell lysate which do not express UNC13A. As well as overexpression experiments with GFP tagged UNC13A.

Rb anti-UNC13B (abcam ab97924) was validated with overexpression experiments with GFP tagged UNC13B.

Rat anti-Tubulin (abcam ab6161) has been cited in > 126 publications.

Rabbit anti-TDP-43 10782-2-AP (Proteintech) has been cited in >1200 publications. Rabbit anti-TDP-43 10782-2-AP (Proteintech) has positive WB detection in SH-SY5Y cells, HeLa cells, K-562 cells, C2C12 cells, Neuro-2a cells, Positive IHC detected in mouse brain tissue, human brain tissue, human brain (FTLD-U) tissue, human gliomas tissue, human pancreas tissue, rat brain tissue. Positive IF detected in HeLa cells, SH-SY5Y cells, Positive FC detected in HeLa cells.

Goat anti-Rabbit HRP (Bio-Rad 1706515) according to manufacturer's website has been double-affinity purified with human IgG adsorbed.

Goat anti-Mouse HRP (Bio-Rad 1706516) has been used in >1000 citations.

Rabbit anti-Rat HRP (Dako P0450) has been used in 120 citations.

Donkey anti-Rabbit 488 (Jackson Immuno 711-545-152) has been used in 705 citations - <https://www.jacksonimmuno.com/catalog/products/711-545-152>

Donkey anti-Mouse 647 (Jackson Immuno 715-605-151) has been used in 121 citations - <https://www.jacksonimmuno.com/catalog/products/715-605-151>

Rabbit anti-TDP-43 (Proteintech 12892-1-AP) has been used in 321 citations <https://www.ptglab.com/Products/TARDBP-Antibody-12892-1-AP.htm>

Mouse anti-TUBB3 (Biolegend 801201) has been used in 597 citations <https://www.biolegend.com/en-us/search-results/purified-anti-tubulin-beta-3-tubb3-antibody-11580>

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)

iPS-derived cortical neurons are from the WTC11 line, which was derived from a healthy human male participant and NCRM5, which was derived from a healthy human male's cord blood and obtained from the Coriell cell repository. All policies of the NIH Intramural Research Program for the registration and use of this iPS cell line were followed. HEK293T and

Authentication	SH-SY5Y cells were obtained from ATCC. SK-N-DZ cells were obtained from the International Centre for Genetic Engineering and Biotechnology in Trieste, Italy.
Mycoplasma contamination	WTC11 iPS cell line was validated to have a normal male karyotype NCRM5 iPS cell line was validated to have a normal male karyotype
Commonly misidentified lines (See ICLAC register)	No commonly misidentified cell lines were used in this study.

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	1349 tissue samples from 377 unique participants (164 female). 77 controls - Median age 67, 239 ALS - Median age 66, 61 FTLD - Median age 67
Recruitment	In NYGC ALS Consortium recruitment and contribution postmortem samples and clinical information was performed by members using their recruitment criteria and strategy.
Ethics oversight	The NYGC ALS Consortium samples presented in this work were acquired through various IRB protocols from member sites and the Target ALS postmortem tissue core and transferred to the NYGC in accordance with all applicable foreign, domestic, federal, state, and local laws and regulations for processing, sequencing, and analyses. The Biomedical Research 3 Alliance of New York (BRANY) IRB serves as the central ethics oversight body for NYGC ALS Consortium. Ethical approval was given and is effective through 08/22/2022.

Note that full information on the approval of the study protocol must also be provided in the manuscript.